[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fG2bjwklJ42yupfPsIlO5hOjsWyWNlaMKM2ZCILNxwOw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":85,"rows":92},"Maastricht University Medical Center",[4],842,false,95,25,223166,19,731,[14,17,19,22,24,27,29,32],{"name":15,"count":16},"Obesity",53,{"name":18,"count":11},"Healthy",{"name":20,"count":21},"Breast Cancer",17,{"name":23,"count":21},"Insulin Resistance",{"name":25,"count":26},"Sarcopenia",15,{"name":28,"count":26},"Overweight and Obesity",{"name":30,"count":31},"Atrial Fibrillation",14,{"name":33,"count":31},"Overweight",[35,40,45,50,55,60,65,70,75,80],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT02266615","Biobank Clinical Genetics Maastricht (KG01)","2024-03","Biobanking of biomaterial for future genetic research.",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT03917303","Control Crohn Safe Trial","2024-05","Adalimumab",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT03019471","Non Invasive Cancer Test (NICT): a Proof of Principle Study.","2025-12","Isolation of tumor DNA",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT05367089","The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms","2026-04-22","Fluconazole",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT05463757","Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study","2026-06","Vismodegib",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT05748093","Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat","2026-06-01","Cobicistat",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT06401824","Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases","2026-11-01","Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT04954599","Phase 1\u002F2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI","2027-02","CP-506",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT07485452","Boosting Osimertinib Blood Brain Barrier Penetration","2027-06","Osimertinib & febuxostat",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT05716945","The OPTIMISE Study","2028-09","Fluorometholone 0.1% Oph Susp",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,121,139,161,187,205,229,247,281,303,330,352,376,394,412,438,459,481,514,532,571,599,617,635,660,686,713,731,756,784,802,830,848,874,901,924,947,972,990,1016,1034,1059,1077,1103,1130,1148,1172,1198,1216,1243,1261,1286,1304,1331,1360,1378,1396,1419,1447,1472,1497,1524,1547,1569,1595,1623,1653,1671,1689,1707,1731,1756,1774,1792,1816,1844,1862,1887,1905,1928,1953,1978,2013,2047,2069,2087,2114,2132,2150,2175,2198,2223,2247,2271,2299,2317,2341,2367,2391,2415,2438,2463,2498,2532,2566,2592,2610,2637,2662,2684,2708,2733,2751,2775,2799,2827,2845,2863,2887,2913,2931,2955,2973,2996,3024,3049,3067,3092,3115,3138,3162,3188,3212,3236,3261,3284,3306,3340,3358,3376,3394,3412,3430,3454,3472,3499,3517,3535,3553,3571,3596,3614,3636,3659],{"intervention":84,"totalTrials":94,"cells":95},1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":119},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":94,"soonestReadout":83},[107],{"nctId":81,"briefTitle":82,"status":108,"phases":109,"primaryCompletion":83,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":117},"RECRUITING",[90],"2029-03","2024-07-29",342,[114,115,116],"Pseudophakic Bullous Keratopathy","Fuchs' Endothelial Dystrophy","Intraocular Pressure",[84,118],"Dexamethasone 0.1% ophthalmic suspension",{"trials":120,"activeCount":98},[],{"intervention":118,"totalTrials":94,"cells":122},{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":129,"PHASE4":131,"NA":137},{"trials":124,"activeCount":98},[],{"trials":126,"activeCount":98},[],{"trials":128,"activeCount":98},[],{"trials":130,"activeCount":98},[],{"trials":132,"activeCount":94,"soonestReadout":83},[133],{"nctId":81,"briefTitle":82,"status":108,"phases":134,"primaryCompletion":83,"completion":110,"start":111,"enrollment":112,"conditions":135,"interventions":136},[90],[114,115,116],[84,118],{"trials":138,"activeCount":98},[],{"intervention":64,"totalTrials":94,"cells":140},{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":159},{"trials":142,"activeCount":98},[],{"trials":144,"activeCount":98},[],{"trials":146,"activeCount":98},[],{"trials":148,"activeCount":98},[],{"trials":150,"activeCount":94,"soonestReadout":63},[151],{"nctId":61,"briefTitle":62,"status":108,"phases":152,"primaryCompletion":63,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":158},[90],"2026-09-01","2024-04-01",60,[157],"Non-small Cell Lung Cancer",[64],{"trials":160,"activeCount":98},[],{"intervention":162,"totalTrials":94,"cells":163},"5FU-Calcipotriol",{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":172,"NA":185},{"trials":165,"activeCount":98},[],{"trials":167,"activeCount":98},[],{"trials":169,"activeCount":98},[],{"trials":171,"activeCount":98},[],{"trials":173,"activeCount":94,"soonestReadout":178},[174],{"nctId":175,"briefTitle":176,"status":108,"phases":177,"primaryCompletion":178,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":183},"NCT06499415","Combination Therapy of 5-Fluorouracil and CALcipotriol Versus 5-Fluorouracil in the Treatment of Actinic Keratosis",[90],"2029-03-02","2024-09-04",232,[182],"Actinic Keratoses",[162,184],"5-FU 50 MG\u002FML Topical Cream",{"trials":186,"activeCount":98},[],{"intervention":184,"totalTrials":94,"cells":188},{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":195,"PHASE4":197,"NA":203},{"trials":190,"activeCount":98},[],{"trials":192,"activeCount":98},[],{"trials":194,"activeCount":98},[],{"trials":196,"activeCount":98},[],{"trials":198,"activeCount":94,"soonestReadout":178},[199],{"nctId":175,"briefTitle":176,"status":108,"phases":200,"primaryCompletion":178,"completion":178,"start":179,"enrollment":180,"conditions":201,"interventions":202},[90],[182],[162,184],{"trials":204,"activeCount":98},[],{"intervention":44,"totalTrials":94,"cells":206},{"EARLY_PHASE1":207,"PHASE1":209,"PHASE2":211,"PHASE3":213,"PHASE4":215,"NA":227},{"trials":208,"activeCount":98},[],{"trials":210,"activeCount":98},[],{"trials":212,"activeCount":98},[],{"trials":214,"activeCount":98},[],{"trials":216,"activeCount":94,"soonestReadout":43},[217],{"nctId":41,"briefTitle":42,"status":108,"phases":218,"primaryCompletion":43,"completion":219,"start":220,"enrollment":221,"conditions":222,"interventions":225},[90],"2026-09","2019-12-23",158,[223,224],"Crohn Disease","Inflammatory Bowel Diseases",[44,226],"standard step-up care",{"trials":228,"activeCount":98},[],{"intervention":226,"totalTrials":94,"cells":230},{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":237,"PHASE4":239,"NA":245},{"trials":232,"activeCount":98},[],{"trials":234,"activeCount":98},[],{"trials":236,"activeCount":98},[],{"trials":238,"activeCount":98},[],{"trials":240,"activeCount":94,"soonestReadout":43},[241],{"nctId":41,"briefTitle":42,"status":108,"phases":242,"primaryCompletion":43,"completion":219,"start":220,"enrollment":221,"conditions":243,"interventions":244},[90],[223,224],[44,226],{"trials":246,"activeCount":98},[],{"intervention":54,"totalTrials":248,"cells":249},2,{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":256,"PHASE4":267,"NA":279},{"trials":251,"activeCount":98},[],{"trials":253,"activeCount":98},[],{"trials":255,"activeCount":98},[],{"trials":257,"activeCount":94,"soonestReadout":53},[258],{"nctId":51,"briefTitle":52,"status":108,"phases":259,"primaryCompletion":53,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":266},[89],"2027-04-22","2022-08-22",252,[264,265],"Candidiasis, Vulvovaginal","Recurrent Candidiasis of Vagina",[54],{"trials":268,"activeCount":98},[269],{"nctId":270,"briefTitle":271,"status":272,"phases":273,"primaryCompletion":274,"completion":275,"start":276,"enrollment":262,"conditions":277,"interventions":278},"NCT04626258","Fluconazol Versus Medical Honey in the Treatment of Recurrent Vulvovaginal Candidiasis","UNKNOWN",[90],"2024-03-01","2025-03-01","2021-03-01",[264,265],[54],{"trials":280,"activeCount":98},[],{"intervention":69,"totalTrials":94,"cells":282},{"EARLY_PHASE1":283,"PHASE1":285,"PHASE2":287,"PHASE3":297,"PHASE4":299,"NA":301},{"trials":284,"activeCount":98},[],{"trials":286,"activeCount":98},[],{"trials":288,"activeCount":94,"soonestReadout":68},[289],{"nctId":66,"briefTitle":67,"status":108,"phases":290,"primaryCompletion":68,"completion":291,"start":292,"enrollment":9,"conditions":293,"interventions":296},[88],"2027-04-01","2025-04-24",[294,295],"NSCLC Stage IV","Brain Metastases, Adult",[69],{"trials":298,"activeCount":98},[],{"trials":300,"activeCount":98},[],{"trials":302,"activeCount":98},[],{"intervention":304,"totalTrials":94,"cells":305},"Tarlatamab",{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":310,"PHASE3":324,"PHASE4":326,"NA":328},{"trials":307,"activeCount":98},[],{"trials":309,"activeCount":98},[],{"trials":311,"activeCount":94,"soonestReadout":317},[312],{"nctId":313,"briefTitle":314,"status":315,"phases":316,"primaryCompletion":317,"completion":318,"start":319,"enrollment":320,"conditions":321,"interventions":323},"NCT07402343","Tarlatamab for SCLC Brain Metastases","NOT_YET_RECRUITING",[88],"2029-02","2030-02","2026-05",35,[322,295],"Small Cell Lung Cancer",[304],{"trials":325,"activeCount":98},[],{"trials":327,"activeCount":98},[],{"trials":329,"activeCount":98},[],{"intervention":79,"totalTrials":94,"cells":331},{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":346,"PHASE4":348,"NA":350},{"trials":333,"activeCount":98},[],{"trials":335,"activeCount":98},[],{"trials":337,"activeCount":94,"soonestReadout":78},[338],{"nctId":76,"briefTitle":77,"status":315,"phases":339,"primaryCompletion":78,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":345},[88],"2028-06","2026-04",7,[344],"Non-Small Cell Lung Cancer",[79],{"trials":347,"activeCount":98},[],{"trials":349,"activeCount":98},[],{"trials":351,"activeCount":98},[],{"intervention":74,"totalTrials":94,"cells":353},{"EARLY_PHASE1":354,"PHASE1":356,"PHASE2":358,"PHASE3":370,"PHASE4":372,"NA":374},{"trials":355,"activeCount":98},[],{"trials":357,"activeCount":98},[],{"trials":359,"activeCount":94,"soonestReadout":73},[360],{"nctId":71,"briefTitle":72,"status":108,"phases":361,"primaryCompletion":73,"completion":362,"start":363,"enrollment":364,"conditions":365,"interventions":367},[87,88],"2027-05","2023-05-30",126,[366],"Unspecified Adult Solid Tumor, Protocol Specific",[74,368,369],"Carboplatin","Immune checkpoint inhibitor",{"trials":371,"activeCount":98},[],{"trials":373,"activeCount":98},[],{"trials":375,"activeCount":98},[],{"intervention":368,"totalTrials":94,"cells":377},{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":382,"PHASE3":388,"PHASE4":390,"NA":392},{"trials":379,"activeCount":98},[],{"trials":381,"activeCount":98},[],{"trials":383,"activeCount":94,"soonestReadout":73},[384],{"nctId":71,"briefTitle":72,"status":108,"phases":385,"primaryCompletion":73,"completion":362,"start":363,"enrollment":364,"conditions":386,"interventions":387},[87,88],[366],[74,368,369],{"trials":389,"activeCount":98},[],{"trials":391,"activeCount":98},[],{"trials":393,"activeCount":98},[],{"intervention":369,"totalTrials":94,"cells":395},{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":406,"PHASE4":408,"NA":410},{"trials":397,"activeCount":98},[],{"trials":399,"activeCount":98},[],{"trials":401,"activeCount":94,"soonestReadout":73},[402],{"nctId":71,"briefTitle":72,"status":108,"phases":403,"primaryCompletion":73,"completion":362,"start":363,"enrollment":364,"conditions":404,"interventions":405},[87,88],[366],[74,368,369],{"trials":407,"activeCount":98},[],{"trials":409,"activeCount":98},[],{"trials":411,"activeCount":98},[],{"intervention":413,"totalTrials":94,"cells":414},"Venous blood sampling prior to CCTA.",{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":421,"PHASE4":423,"NA":425},{"trials":416,"activeCount":98},[],{"trials":418,"activeCount":98},[],{"trials":420,"activeCount":98},[],{"trials":422,"activeCount":98},[],{"trials":424,"activeCount":98},[],{"trials":426,"activeCount":94,"soonestReadout":431},[427],{"nctId":428,"briefTitle":429,"status":108,"phases":430,"primaryCompletion":431,"completion":431,"start":432,"enrollment":433,"conditions":434,"interventions":437},"NCT02381301","Biomarkers and Cardiac CT",[],"2029-12","2015-02",5000,[435,436],"Coronary Artery Disease","Atherosclerosis",[413],{"intervention":49,"totalTrials":94,"cells":439},{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":446,"PHASE4":448,"NA":450},{"trials":441,"activeCount":98},[],{"trials":443,"activeCount":98},[],{"trials":445,"activeCount":98},[],{"trials":447,"activeCount":98},[],{"trials":449,"activeCount":98},[],{"trials":451,"activeCount":94,"soonestReadout":48},[452],{"nctId":46,"briefTitle":47,"status":108,"phases":453,"primaryCompletion":48,"completion":48,"start":454,"enrollment":455,"conditions":456,"interventions":458},[],"2016-03-01",40,[457],"Neoplasmata",[49],{"intervention":39,"totalTrials":94,"cells":460},{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":467,"PHASE4":469,"NA":471},{"trials":462,"activeCount":98},[],{"trials":464,"activeCount":98},[],{"trials":466,"activeCount":98},[],{"trials":468,"activeCount":98},[],{"trials":470,"activeCount":98},[],{"trials":472,"activeCount":94,"soonestReadout":38},[473],{"nctId":36,"briefTitle":37,"status":108,"phases":474,"primaryCompletion":38,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":480},[],"2035-01","2014-09",3600,[479],"Genetic Disease",[39],{"intervention":59,"totalTrials":94,"cells":482},{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":489,"PHASE4":491,"NA":493},{"trials":484,"activeCount":98},[],{"trials":486,"activeCount":98},[],{"trials":488,"activeCount":98},[],{"trials":490,"activeCount":98},[],{"trials":492,"activeCount":98},[],{"trials":494,"activeCount":94,"soonestReadout":58},[495],{"nctId":56,"briefTitle":57,"status":108,"phases":496,"primaryCompletion":58,"completion":497,"start":498,"enrollment":499,"conditions":500,"interventions":512},[],"2026-12","2021-11-01",80,[501,502,503,504,505,506,507,508,509,510,511],"Basal Cell Carcinoma","Locally Advanced Basal Cell Carcinoma","Metastatic Basal Cell Carcinoma","Gorlin Syndrome","Basal Cell Nevus Syndrome","Carcinoma, Basal Cell","Carcinoma","Basal Cell Tumor","Skin Cancer","Neoplasm of Skin","Neoplasms, Basal Cell",[59,513],"Sonidegib",{"intervention":513,"totalTrials":94,"cells":515},{"EARLY_PHASE1":516,"PHASE1":518,"PHASE2":520,"PHASE3":522,"PHASE4":524,"NA":526},{"trials":517,"activeCount":98},[],{"trials":519,"activeCount":98},[],{"trials":521,"activeCount":98},[],{"trials":523,"activeCount":98},[],{"trials":525,"activeCount":98},[],{"trials":527,"activeCount":94,"soonestReadout":58},[528],{"nctId":56,"briefTitle":57,"status":108,"phases":529,"primaryCompletion":58,"completion":497,"start":498,"enrollment":499,"conditions":530,"interventions":531},[],[501,502,503,504,505,506,507,508,509,510,511],[59,513],{"intervention":533,"totalTrials":248,"cells":534},"Placebos",{"EARLY_PHASE1":535,"PHASE1":537,"PHASE2":539,"PHASE3":554,"PHASE4":556,"NA":569},{"trials":536,"activeCount":98},[],{"trials":538,"activeCount":98},[],{"trials":540,"activeCount":98},[541],{"nctId":542,"briefTitle":543,"status":544,"phases":545,"primaryCompletion":546,"completion":546,"start":547,"enrollment":548,"conditions":549,"interventions":552},"NCT03964688","Effect of Vitamin C in Autologous Stem Cell Transplantations","COMPLETED",[88],"2022-03-01","2019-12-10",47,[550,551],"Myeloma Multiple","Lymphoma",[553,533],"Vitamin C",{"trials":555,"activeCount":98},[],{"trials":557,"activeCount":98},[558],{"nctId":559,"briefTitle":560,"status":544,"phases":561,"primaryCompletion":562,"completion":562,"start":563,"enrollment":564,"conditions":565,"interventions":567},"NCT03227900","Lidocaine and Food Intake",[90],"2018-06-26","2017-07-19",26,[566],"Hunger",[568,533],"Lidocaine",{"trials":570,"activeCount":98},[],{"intervention":572,"totalTrials":94,"cells":573},"240 mg Iodine",{"EARLY_PHASE1":574,"PHASE1":576,"PHASE2":578,"PHASE3":580,"PHASE4":582,"NA":597},{"trials":575,"activeCount":98},[],{"trials":577,"activeCount":98},[],{"trials":579,"activeCount":98},[],{"trials":581,"activeCount":98},[],{"trials":583,"activeCount":98},[584],{"nctId":585,"briefTitle":586,"status":544,"phases":587,"primaryCompletion":588,"completion":589,"start":590,"enrollment":591,"conditions":592,"interventions":594},"NCT02462044","Contrast Enhancement on Coronary Computed Tomographic Angiography",[90],"2015-08","2015-09","2014-08",200,[435,593],"Coronary Stenosis",[572,595,596],"300 mg Iodine","370 mg Iodine",{"trials":598,"activeCount":98},[],{"intervention":595,"totalTrials":94,"cells":600},{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":609,"NA":615},{"trials":602,"activeCount":98},[],{"trials":604,"activeCount":98},[],{"trials":606,"activeCount":98},[],{"trials":608,"activeCount":98},[],{"trials":610,"activeCount":98},[611],{"nctId":585,"briefTitle":586,"status":544,"phases":612,"primaryCompletion":588,"completion":589,"start":590,"enrollment":591,"conditions":613,"interventions":614},[90],[435,593],[572,595,596],{"trials":616,"activeCount":98},[],{"intervention":596,"totalTrials":94,"cells":618},{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":625,"PHASE4":627,"NA":633},{"trials":620,"activeCount":98},[],{"trials":622,"activeCount":98},[],{"trials":624,"activeCount":98},[],{"trials":626,"activeCount":98},[],{"trials":628,"activeCount":98},[629],{"nctId":585,"briefTitle":586,"status":544,"phases":630,"primaryCompletion":588,"completion":589,"start":590,"enrollment":591,"conditions":631,"interventions":632},[90],[435,593],[572,595,596],{"trials":634,"activeCount":98},[],{"intervention":636,"totalTrials":94,"cells":637},"Euthyrox",{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":644,"PHASE4":646,"NA":658},{"trials":639,"activeCount":98},[],{"trials":641,"activeCount":98},[],{"trials":643,"activeCount":98},[],{"trials":645,"activeCount":98},[],{"trials":647,"activeCount":98},[648],{"nctId":649,"briefTitle":650,"status":272,"phases":651,"primaryCompletion":652,"completion":652,"start":653,"enrollment":21,"conditions":654,"interventions":657},"NCT01379170","Thyroid Study Type 2 Diabetes Mellitus (T2DM)",[90],"2014-12","2011-06",[655,656],"Diabetes","Hypothyroidism",[636],{"trials":659,"activeCount":98},[],{"intervention":661,"totalTrials":94,"cells":662},"Eplerenone",{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":669,"PHASE4":671,"NA":684},{"trials":664,"activeCount":98},[],{"trials":666,"activeCount":98},[],{"trials":668,"activeCount":98},[],{"trials":670,"activeCount":98},[],{"trials":672,"activeCount":98},[673],{"nctId":674,"briefTitle":675,"status":676,"phases":677,"primaryCompletion":678,"completion":678,"start":679,"enrollment":9,"conditions":680,"interventions":683},"NCT01887119","Aldosterone Antagonism and Microvascular Function","TERMINATED",[90],"2018-11","2013-10",[681,23,682],"Abdominal Obesity Metabolic Syndrome","Hypertension",[661],{"trials":685,"activeCount":98},[],{"intervention":687,"totalTrials":94,"cells":688},"Tiotropium 'Respimat' 5 mcg",{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":695,"PHASE4":697,"NA":711},{"trials":690,"activeCount":98},[],{"trials":692,"activeCount":98},[],{"trials":694,"activeCount":98},[],{"trials":696,"activeCount":98},[],{"trials":698,"activeCount":98},[699],{"nctId":700,"briefTitle":701,"status":272,"phases":702,"primaryCompletion":703,"completion":704,"start":705,"enrollment":706,"conditions":707,"interventions":709},"NCT03275116","The Effect of Twice Daily vs. Once Daily Bronchodilation on Hyperinflation in COPD Patients During 24 Hours.",[90],"2020-04","2020-12","2017-07-07",49,[708],"Chronic Obstructive Airway Disease",[687,710],"Aclidinium Bromide\u002FFormoterol Fumarate 340\u002F12 mcg",{"trials":712,"activeCount":98},[],{"intervention":710,"totalTrials":94,"cells":714},{"EARLY_PHASE1":715,"PHASE1":717,"PHASE2":719,"PHASE3":721,"PHASE4":723,"NA":729},{"trials":716,"activeCount":98},[],{"trials":718,"activeCount":98},[],{"trials":720,"activeCount":98},[],{"trials":722,"activeCount":98},[],{"trials":724,"activeCount":98},[725],{"nctId":700,"briefTitle":701,"status":272,"phases":726,"primaryCompletion":703,"completion":704,"start":705,"enrollment":706,"conditions":727,"interventions":728},[90],[708],[687,710],{"trials":730,"activeCount":98},[],{"intervention":732,"totalTrials":94,"cells":733},"Fibrate treatment",{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":740,"PHASE4":742,"NA":754},{"trials":735,"activeCount":98},[],{"trials":737,"activeCount":98},[],{"trials":739,"activeCount":98},[],{"trials":741,"activeCount":98},[],{"trials":743,"activeCount":98},[744],{"nctId":745,"briefTitle":746,"status":544,"phases":747,"primaryCompletion":748,"completion":748,"start":749,"enrollment":750,"conditions":751,"interventions":753},"NCT01527318","The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM)",[90],"2012-12","2011-08",6,[752],"Neutral Lipid Storage Disease",[732],{"trials":755,"activeCount":98},[],{"intervention":757,"totalTrials":94,"cells":758},"Oxycodone",{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":765,"PHASE4":767,"NA":782},{"trials":760,"activeCount":98},[],{"trials":762,"activeCount":98},[],{"trials":764,"activeCount":98},[],{"trials":766,"activeCount":98},[],{"trials":768,"activeCount":98},[769],{"nctId":770,"briefTitle":771,"status":676,"phases":772,"primaryCompletion":773,"completion":773,"start":774,"enrollment":775,"conditions":776,"interventions":780},"NCT03616639","Neurotoxic Adverse Effects of Morphine and Oxycodone for Pain in Terminal Patients With Diminished Renal Function",[90],"2018-12-19","2018-06-04",8,[777,778,779],"Pain","Terminal Illness","Renal Impairment",[757,781],"Morphine",{"trials":783,"activeCount":98},[],{"intervention":781,"totalTrials":94,"cells":785},{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":792,"PHASE4":794,"NA":800},{"trials":787,"activeCount":98},[],{"trials":789,"activeCount":98},[],{"trials":791,"activeCount":98},[],{"trials":793,"activeCount":98},[],{"trials":795,"activeCount":98},[796],{"nctId":770,"briefTitle":771,"status":676,"phases":797,"primaryCompletion":773,"completion":773,"start":774,"enrollment":775,"conditions":798,"interventions":799},[90],[777,778,779],[757,781],{"trials":801,"activeCount":98},[],{"intervention":803,"totalTrials":94,"cells":804},"5-fluorouracil",{"EARLY_PHASE1":805,"PHASE1":807,"PHASE2":809,"PHASE3":811,"PHASE4":813,"NA":828},{"trials":806,"activeCount":98},[],{"trials":808,"activeCount":98},[],{"trials":810,"activeCount":98},[],{"trials":812,"activeCount":98},[],{"trials":814,"activeCount":98},[815],{"nctId":816,"briefTitle":817,"status":272,"phases":818,"primaryCompletion":819,"completion":820,"start":821,"enrollment":822,"conditions":823,"interventions":825},"NCT02281682","IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis",[90],"2018-07","2018-12","2014-11",624,[824],"Keratosis, Actinic",[826,803,827],"Imiquimod","Ingenol mebutate",{"trials":829,"activeCount":98},[],{"intervention":827,"totalTrials":94,"cells":831},{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":838,"PHASE4":840,"NA":846},{"trials":833,"activeCount":98},[],{"trials":835,"activeCount":98},[],{"trials":837,"activeCount":98},[],{"trials":839,"activeCount":98},[],{"trials":841,"activeCount":98},[842],{"nctId":816,"briefTitle":817,"status":272,"phases":843,"primaryCompletion":819,"completion":820,"start":821,"enrollment":822,"conditions":844,"interventions":845},[90],[824],[826,803,827],{"trials":847,"activeCount":98},[],{"intervention":849,"totalTrials":94,"cells":850},"Escitalopram",{"EARLY_PHASE1":851,"PHASE1":853,"PHASE2":855,"PHASE3":857,"PHASE4":859,"NA":872},{"trials":852,"activeCount":98},[],{"trials":854,"activeCount":98},[],{"trials":856,"activeCount":98},[],{"trials":858,"activeCount":98},[],{"trials":860,"activeCount":98},[861],{"nctId":862,"briefTitle":863,"status":544,"phases":864,"primaryCompletion":865,"completion":865,"start":866,"enrollment":867,"conditions":868,"interventions":871},"NCT01551225","Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder",[90],"2016-09","2012-01",32,[869,870],"Irritable Bowel Syndrome","Panic Disorder",[849],{"trials":873,"activeCount":98},[],{"intervention":875,"totalTrials":94,"cells":876},"Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment",{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":881,"PHASE3":883,"PHASE4":885,"NA":899},{"trials":878,"activeCount":98},[],{"trials":880,"activeCount":98},[],{"trials":882,"activeCount":98},[],{"trials":884,"activeCount":98},[],{"trials":886,"activeCount":98},[887],{"nctId":888,"briefTitle":889,"status":272,"phases":890,"primaryCompletion":891,"completion":892,"start":893,"enrollment":894,"conditions":895,"interventions":898},"NCT06046612","Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction",[90],"2024-08-13","2025-02-13","2023-02-13",48,[896,897],"Heart Failure With Preserved Ejection Fraction","Microvascular Dysfunction",[875],{"trials":900,"activeCount":98},[],{"intervention":902,"totalTrials":94,"cells":903},"Gadofosveset trisodium",{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":910,"PHASE4":912,"NA":922},{"trials":905,"activeCount":98},[],{"trials":907,"activeCount":98},[],{"trials":909,"activeCount":98},[],{"trials":911,"activeCount":98},[],{"trials":913,"activeCount":98},[914],{"nctId":915,"briefTitle":916,"status":917,"phases":918,"primaryCompletion":476,"completion":476,"start":476,"enrollment":98,"conditions":919,"interventions":921},"NCT02243059","Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer","WITHDRAWN",[90],[920],"Ovarian Neoplasms",[902],{"trials":923,"activeCount":98},[],{"intervention":925,"totalTrials":94,"cells":926},"Methylphenidate",{"EARLY_PHASE1":927,"PHASE1":929,"PHASE2":931,"PHASE3":933,"PHASE4":935,"NA":945},{"trials":928,"activeCount":98},[],{"trials":930,"activeCount":98},[],{"trials":932,"activeCount":98},[],{"trials":934,"activeCount":98},[],{"trials":936,"activeCount":98},[937],{"nctId":938,"briefTitle":939,"status":272,"phases":940,"primaryCompletion":941,"completion":941,"start":821,"enrollment":455,"conditions":942,"interventions":944},"NCT02326038","Ritalin, Memory and Attention in MCI: a Behaviour-EEG Study",[90],"2015-12",[943],"Mild Cognitive Impairment",[925],{"trials":946,"activeCount":98},[],{"intervention":948,"totalTrials":94,"cells":949},"Liraglutide",{"EARLY_PHASE1":950,"PHASE1":952,"PHASE2":954,"PHASE3":956,"PHASE4":958,"NA":970},{"trials":951,"activeCount":98},[],{"trials":953,"activeCount":98},[],{"trials":955,"activeCount":98},[],{"trials":957,"activeCount":98},[],{"trials":959,"activeCount":98},[960],{"nctId":961,"briefTitle":962,"status":676,"phases":963,"primaryCompletion":964,"completion":964,"start":965,"enrollment":966,"conditions":967,"interventions":969},"NCT01638260","GLP-1 and Non-exercise Activity Thermogenesis in RHZ",[90],"2013-11","2012-10",22,[968],"Type 2 Diabetes Mellitus",[948],{"trials":971,"activeCount":98},[],{"intervention":568,"totalTrials":94,"cells":973},{"EARLY_PHASE1":974,"PHASE1":976,"PHASE2":978,"PHASE3":980,"PHASE4":982,"NA":988},{"trials":975,"activeCount":98},[],{"trials":977,"activeCount":98},[],{"trials":979,"activeCount":98},[],{"trials":981,"activeCount":98},[],{"trials":983,"activeCount":98},[984],{"nctId":559,"briefTitle":560,"status":544,"phases":985,"primaryCompletion":562,"completion":562,"start":563,"enrollment":564,"conditions":986,"interventions":987},[90],[566],[568,533],{"trials":989,"activeCount":98},[],{"intervention":991,"totalTrials":94,"cells":992},"fentanyl",{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":999,"PHASE4":1001,"NA":1014},{"trials":994,"activeCount":98},[],{"trials":996,"activeCount":98},[],{"trials":998,"activeCount":98},[],{"trials":1000,"activeCount":98},[],{"trials":1002,"activeCount":98},[1003],{"nctId":1004,"briefTitle":1005,"status":544,"phases":1006,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":1010,"interventions":1012},"NCT01317589","Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective?",[90],"2015-07","2011-05",134,[777,1011],"Cancer of Head and Neck",[991,1013],"methadone",{"trials":1015,"activeCount":98},[],{"intervention":1013,"totalTrials":94,"cells":1017},{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1024,"PHASE4":1026,"NA":1032},{"trials":1019,"activeCount":98},[],{"trials":1021,"activeCount":98},[],{"trials":1023,"activeCount":98},[],{"trials":1025,"activeCount":98},[],{"trials":1027,"activeCount":98},[1028],{"nctId":1004,"briefTitle":1005,"status":544,"phases":1029,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":1030,"interventions":1031},[90],[777,1011],[991,1013],{"trials":1033,"activeCount":98},[],{"intervention":1035,"totalTrials":94,"cells":1036},"Vernakalant",{"EARLY_PHASE1":1037,"PHASE1":1039,"PHASE2":1041,"PHASE3":1043,"PHASE4":1045,"NA":1057},{"trials":1038,"activeCount":98},[],{"trials":1040,"activeCount":98},[],{"trials":1042,"activeCount":98},[],{"trials":1044,"activeCount":98},[],{"trials":1046,"activeCount":98},[1047],{"nctId":1048,"briefTitle":1049,"status":272,"phases":1050,"primaryCompletion":1051,"completion":1051,"start":1052,"enrollment":1053,"conditions":1054,"interventions":1055},"NCT01646281","Vernakalant Versus Flecainide: Atrial Contractility",[90],"2013-08","2012-08",70,[30],[1035,1056],"Flecainide",{"trials":1058,"activeCount":98},[],{"intervention":1056,"totalTrials":94,"cells":1060},{"EARLY_PHASE1":1061,"PHASE1":1063,"PHASE2":1065,"PHASE3":1067,"PHASE4":1069,"NA":1075},{"trials":1062,"activeCount":98},[],{"trials":1064,"activeCount":98},[],{"trials":1066,"activeCount":98},[],{"trials":1068,"activeCount":98},[],{"trials":1070,"activeCount":98},[1071],{"nctId":1048,"briefTitle":1049,"status":272,"phases":1072,"primaryCompletion":1051,"completion":1051,"start":1052,"enrollment":1053,"conditions":1073,"interventions":1074},[90],[30],[1035,1056],{"trials":1076,"activeCount":98},[],{"intervention":1078,"totalTrials":94,"cells":1079},"sustained release morphine",{"EARLY_PHASE1":1080,"PHASE1":1082,"PHASE2":1084,"PHASE3":1086,"PHASE4":1088,"NA":1101},{"trials":1081,"activeCount":98},[],{"trials":1083,"activeCount":98},[],{"trials":1085,"activeCount":98},[],{"trials":1087,"activeCount":98},[],{"trials":1089,"activeCount":98},[1090],{"nctId":1091,"briefTitle":1092,"status":544,"phases":1093,"primaryCompletion":1094,"completion":1095,"start":1096,"enrollment":1097,"conditions":1098,"interventions":1100},"NCT02429050","Morphine for Treatment of Dyspnea in Patients With COPD",[90],"2019-03-06","2019-07-01","2016-11-16",124,[1099],"Pulmonary Disease, Chronic Obstructive",[1078],{"trials":1102,"activeCount":98},[],{"intervention":1104,"totalTrials":94,"cells":1105},"Ferinject",{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1110,"PHASE3":1112,"PHASE4":1114,"NA":1128},{"trials":1107,"activeCount":98},[],{"trials":1109,"activeCount":98},[],{"trials":1111,"activeCount":98},[],{"trials":1113,"activeCount":98},[],{"trials":1115,"activeCount":98},[1116],{"nctId":1117,"briefTitle":1118,"status":676,"phases":1119,"primaryCompletion":1120,"completion":1121,"start":1122,"enrollment":1123,"conditions":1124,"interventions":1126},"NCT01975272","The Use of Iron Therapy for Patients With Anemia After Caesarean Section",[90],"2018-05-17","2018-06-21","2015-03-02",27,[1125],"Postoperative Anaemia",[1104,1127],"Ferrous fumarate",{"trials":1129,"activeCount":98},[],{"intervention":1127,"totalTrials":94,"cells":1131},{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1136,"PHASE3":1138,"PHASE4":1140,"NA":1146},{"trials":1133,"activeCount":98},[],{"trials":1135,"activeCount":98},[],{"trials":1137,"activeCount":98},[],{"trials":1139,"activeCount":98},[],{"trials":1141,"activeCount":98},[1142],{"nctId":1117,"briefTitle":1118,"status":676,"phases":1143,"primaryCompletion":1120,"completion":1121,"start":1122,"enrollment":1123,"conditions":1144,"interventions":1145},[90],[1125],[1104,1127],{"trials":1147,"activeCount":98},[],{"intervention":1149,"totalTrials":94,"cells":1150},"Movicol",{"EARLY_PHASE1":1151,"PHASE1":1153,"PHASE2":1155,"PHASE3":1157,"PHASE4":1159,"NA":1170},{"trials":1152,"activeCount":98},[],{"trials":1154,"activeCount":98},[],{"trials":1156,"activeCount":98},[],{"trials":1158,"activeCount":98},[],{"trials":1160,"activeCount":98},[1161],{"nctId":1162,"briefTitle":1163,"status":272,"phases":1164,"primaryCompletion":1165,"start":1166,"enrollment":499,"conditions":1167,"interventions":1169},"NCT01429779","The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme",[90],"2014-10","2012-07",[1168],"Liver Diseases",[1149],{"trials":1171,"activeCount":98},[],{"intervention":1173,"totalTrials":94,"cells":1174},"PCM\u002FOxy1",{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1179,"PHASE3":1181,"PHASE4":1183,"NA":1196},{"trials":1176,"activeCount":98},[],{"trials":1178,"activeCount":98},[],{"trials":1180,"activeCount":98},[],{"trials":1182,"activeCount":98},[],{"trials":1184,"activeCount":98},[1185],{"nctId":1186,"briefTitle":1187,"status":544,"phases":1188,"primaryCompletion":1189,"start":1190,"enrollment":1191,"conditions":1192,"interventions":1194},"NCT02152592","Controlled-Release Oxycodone Versus Naproxen at Home After Ambulatory Surgery: A Randomized Controlled Trial",[90],"2009-03","2007-10",105,[1193],"Postoperative Pain After Ambulatory Surgery",[1173,1195],"PCM\u002FOxy2",{"trials":1197,"activeCount":98},[],{"intervention":1195,"totalTrials":94,"cells":1199},{"EARLY_PHASE1":1200,"PHASE1":1202,"PHASE2":1204,"PHASE3":1206,"PHASE4":1208,"NA":1214},{"trials":1201,"activeCount":98},[],{"trials":1203,"activeCount":98},[],{"trials":1205,"activeCount":98},[],{"trials":1207,"activeCount":98},[],{"trials":1209,"activeCount":98},[1210],{"nctId":1186,"briefTitle":1187,"status":544,"phases":1211,"primaryCompletion":1189,"start":1190,"enrollment":1191,"conditions":1212,"interventions":1213},[90],[1193],[1173,1195],{"trials":1215,"activeCount":98},[],{"intervention":1217,"totalTrials":94,"cells":1218},"Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram",{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1225,"PHASE4":1227,"NA":1241},{"trials":1220,"activeCount":98},[],{"trials":1222,"activeCount":98},[],{"trials":1224,"activeCount":98},[],{"trials":1226,"activeCount":98},[],{"trials":1228,"activeCount":98},[1229],{"nctId":1230,"briefTitle":1231,"status":544,"phases":1232,"primaryCompletion":1233,"completion":1234,"start":1235,"enrollment":1236,"conditions":1237,"interventions":1239},"NCT03909646","Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease",[90],"2022-03-02","2024-12-12","2019-05-27",250,[1238],"Bowen's Disease",[1217,1240],"5Fluorouracil",{"trials":1242,"activeCount":98},[],{"intervention":1240,"totalTrials":94,"cells":1244},{"EARLY_PHASE1":1245,"PHASE1":1247,"PHASE2":1249,"PHASE3":1251,"PHASE4":1253,"NA":1259},{"trials":1246,"activeCount":98},[],{"trials":1248,"activeCount":98},[],{"trials":1250,"activeCount":98},[],{"trials":1252,"activeCount":98},[],{"trials":1254,"activeCount":98},[1255],{"nctId":1230,"briefTitle":1231,"status":544,"phases":1256,"primaryCompletion":1233,"completion":1234,"start":1235,"enrollment":1236,"conditions":1257,"interventions":1258},[90],[1238],[1217,1240],{"trials":1260,"activeCount":98},[],{"intervention":1262,"totalTrials":94,"cells":1263},"Methylaminolevulinate PDT in 2 sessions",{"EARLY_PHASE1":1264,"PHASE1":1266,"PHASE2":1268,"PHASE3":1270,"PHASE4":1272,"NA":1284},{"trials":1265,"activeCount":98},[],{"trials":1267,"activeCount":98},[],{"trials":1269,"activeCount":98},[],{"trials":1271,"activeCount":98},[],{"trials":1273,"activeCount":98},[1274],{"nctId":1275,"briefTitle":1276,"status":272,"phases":1277,"primaryCompletion":1278,"completion":1278,"start":1051,"enrollment":1279,"conditions":1280,"interventions":1282},"NCT01491711","Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate",[90],"2015-04",162,[1281],"Superficial Basal Cell Carcinoma",[1262,1283],"Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT",{"trials":1285,"activeCount":98},[],{"intervention":1283,"totalTrials":94,"cells":1287},{"EARLY_PHASE1":1288,"PHASE1":1290,"PHASE2":1292,"PHASE3":1294,"PHASE4":1296,"NA":1302},{"trials":1289,"activeCount":98},[],{"trials":1291,"activeCount":98},[],{"trials":1293,"activeCount":98},[],{"trials":1295,"activeCount":98},[],{"trials":1297,"activeCount":98},[1298],{"nctId":1275,"briefTitle":1276,"status":272,"phases":1299,"primaryCompletion":1278,"completion":1278,"start":1051,"enrollment":1279,"conditions":1300,"interventions":1301},[90],[1281],[1262,1283],{"trials":1303,"activeCount":98},[],{"intervention":1305,"totalTrials":94,"cells":1306},"sertraline",{"EARLY_PHASE1":1307,"PHASE1":1309,"PHASE2":1311,"PHASE3":1313,"PHASE4":1315,"NA":1329},{"trials":1308,"activeCount":98},[],{"trials":1310,"activeCount":98},[],{"trials":1312,"activeCount":98},[],{"trials":1314,"activeCount":98},[],{"trials":1316,"activeCount":98},[1317],{"nctId":1318,"briefTitle":1319,"status":544,"phases":1320,"primaryCompletion":1321,"completion":1321,"start":1322,"enrollment":1323,"conditions":1324,"interventions":1328},"NCT01114100","The Effects of Treatment With Sertraline for Noncardiac Chest Pain",[90],"2002-12","2000-01",210,[1325,1326,1327],"Panic Attacks","Chest Pain","Depression",[1305],{"trials":1330,"activeCount":98},[],{"intervention":1332,"totalTrials":94,"cells":1333},"Labetalol",{"EARLY_PHASE1":1334,"PHASE1":1336,"PHASE2":1338,"PHASE3":1340,"PHASE4":1342,"NA":1358},{"trials":1335,"activeCount":98},[],{"trials":1337,"activeCount":98},[],{"trials":1339,"activeCount":98},[],{"trials":1341,"activeCount":98},[],{"trials":1343,"activeCount":98},[1344],{"nctId":1345,"briefTitle":1346,"status":272,"phases":1347,"primaryCompletion":1348,"completion":1349,"start":1350,"enrollment":1351,"conditions":1352,"interventions":1355},"NCT02531490","Early Vascular Adjustments During Hypertensive Pregnancy",[90],"2023-02","2023-04","2015-01-01",368,[1353,1354],"Hypertension, Pregnancy-Induced","Pre-Eclampsia",[1332,1356,1357],"Nifedipine","Methyldopa",{"trials":1359,"activeCount":98},[],{"intervention":1356,"totalTrials":94,"cells":1361},{"EARLY_PHASE1":1362,"PHASE1":1364,"PHASE2":1366,"PHASE3":1368,"PHASE4":1370,"NA":1376},{"trials":1363,"activeCount":98},[],{"trials":1365,"activeCount":98},[],{"trials":1367,"activeCount":98},[],{"trials":1369,"activeCount":98},[],{"trials":1371,"activeCount":98},[1372],{"nctId":1345,"briefTitle":1346,"status":272,"phases":1373,"primaryCompletion":1348,"completion":1349,"start":1350,"enrollment":1351,"conditions":1374,"interventions":1375},[90],[1353,1354],[1332,1356,1357],{"trials":1377,"activeCount":98},[],{"intervention":1357,"totalTrials":94,"cells":1379},{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1386,"PHASE4":1388,"NA":1394},{"trials":1381,"activeCount":98},[],{"trials":1383,"activeCount":98},[],{"trials":1385,"activeCount":98},[],{"trials":1387,"activeCount":98},[],{"trials":1389,"activeCount":98},[1390],{"nctId":1345,"briefTitle":1346,"status":272,"phases":1391,"primaryCompletion":1348,"completion":1349,"start":1350,"enrollment":1351,"conditions":1392,"interventions":1393},[90],[1353,1354],[1332,1356,1357],{"trials":1395,"activeCount":98},[],{"intervention":1397,"totalTrials":94,"cells":1398},"Ribavirin",{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1403,"PHASE3":1405,"PHASE4":1407,"NA":1417},{"trials":1400,"activeCount":98},[],{"trials":1402,"activeCount":98},[],{"trials":1404,"activeCount":98},[],{"trials":1406,"activeCount":98},[],{"trials":1408,"activeCount":98},[1409],{"nctId":1410,"briefTitle":1411,"status":544,"phases":1412,"primaryCompletion":748,"completion":748,"start":1413,"enrollment":26,"conditions":1414,"interventions":1416},"NCT00484328","Ribavirin, Its Dosing Regime",[90],"2007-07",[1415],"Hepatitis C",[1397],{"trials":1418,"activeCount":98},[],{"intervention":1420,"totalTrials":94,"cells":1421},"Ciprofibrate 100Mg",{"EARLY_PHASE1":1422,"PHASE1":1424,"PHASE2":1426,"PHASE3":1428,"PHASE4":1443,"NA":1445},{"trials":1423,"activeCount":98},[],{"trials":1425,"activeCount":98},[],{"trials":1427,"activeCount":98},[],{"trials":1429,"activeCount":98},[1430],{"nctId":1431,"briefTitle":1432,"status":544,"phases":1433,"primaryCompletion":1434,"completion":1435,"start":1436,"enrollment":1437,"conditions":1438,"interventions":1442},"NCT03662984","Ciprofibrate and Pre-diabetes",[89],"2020-11-06","2020-11-13","2018-11-01",11,[1439,1440,1441],"Myocardial Insulin Sensitivity","Impaired Glucose Metabolism","Diastolic Dysfunction",[1420],{"trials":1444,"activeCount":98},[],{"trials":1446,"activeCount":98},[],{"intervention":1448,"totalTrials":94,"cells":1449},"Hydroxyethylrutoside",{"EARLY_PHASE1":1450,"PHASE1":1452,"PHASE2":1454,"PHASE3":1456,"PHASE4":1468,"NA":1470},{"trials":1451,"activeCount":98},[],{"trials":1453,"activeCount":98},[],{"trials":1455,"activeCount":98},[],{"trials":1457,"activeCount":98},[1458],{"nctId":1459,"briefTitle":1460,"status":544,"phases":1461,"primaryCompletion":1462,"completion":1462,"start":1463,"enrollment":1464,"conditions":1465,"interventions":1467},"NCT04670432","Resolution Enhancement by a Supplemental Obstruction Lessening Venoactive Drug for Eight Weeks in Deep Vein Thrombosis",[89],"2023-11-28","2020-12-08",44,[1466],"Deep Vein Thrombosis",[1448],{"trials":1469,"activeCount":98},[],{"trials":1471,"activeCount":98},[],{"intervention":1473,"totalTrials":94,"cells":1474},"L-arginine",{"EARLY_PHASE1":1475,"PHASE1":1477,"PHASE2":1479,"PHASE3":1481,"PHASE4":1493,"NA":1495},{"trials":1476,"activeCount":98},[],{"trials":1478,"activeCount":98},[],{"trials":1480,"activeCount":98},[],{"trials":1482,"activeCount":98},[1483],{"nctId":1484,"briefTitle":1485,"status":272,"phases":1486,"primaryCompletion":1487,"completion":941,"start":821,"enrollment":564,"conditions":1488,"interventions":1492},"NCT02291458","L-arginine and Brown Adipose Tissue",[89],"2015-10",[1489,1490,1491],"Adipose Tissue, Brown","Glucose Intolerance","Nitric Oxide",[1473],{"trials":1494,"activeCount":98},[],{"trials":1496,"activeCount":98},[],{"intervention":1498,"totalTrials":94,"cells":1499},"Pilocarpine",{"EARLY_PHASE1":1500,"PHASE1":1502,"PHASE2":1504,"PHASE3":1506,"PHASE4":1520,"NA":1522},{"trials":1501,"activeCount":98},[],{"trials":1503,"activeCount":98},[],{"trials":1505,"activeCount":98},[],{"trials":1507,"activeCount":98},[1508],{"nctId":1509,"briefTitle":1510,"status":272,"phases":1511,"primaryCompletion":1512,"completion":1513,"start":1514,"enrollment":1515,"conditions":1516,"interventions":1519},"NCT05506137","Xerostomia in Patients With a Life-limiting Condition or Frailty",[89],"2025-02","2025-06","2023-01",120,[1517,1518],"Xerostomia","Dry Mouth",[1498],{"trials":1521,"activeCount":98},[],{"trials":1523,"activeCount":98},[],{"intervention":1525,"totalTrials":94,"cells":1526},"18F-Flutemetamol PET\u002FMRI",{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1531,"PHASE3":1533,"PHASE4":1543,"NA":1545},{"trials":1528,"activeCount":98},[],{"trials":1530,"activeCount":98},[],{"trials":1532,"activeCount":98},[],{"trials":1534,"activeCount":98},[1535],{"nctId":1536,"briefTitle":1537,"status":272,"phases":1538,"primaryCompletion":1539,"completion":1539,"start":1540,"enrollment":9,"conditions":1541,"interventions":1542},"NCT03291093","18F-Flutemetamol and Plaque Vulnerability",[88,89],"2019-12-31","2018-02-01",[436],[1525],{"trials":1544,"activeCount":98},[],{"trials":1546,"activeCount":98},[],{"intervention":1548,"totalTrials":94,"cells":1549},"18F-choline PET-MR imaging",{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1554,"PHASE3":1556,"PHASE4":1565,"NA":1567},{"trials":1551,"activeCount":98},[],{"trials":1553,"activeCount":98},[],{"trials":1555,"activeCount":98},[],{"trials":1557,"activeCount":98},[1558],{"nctId":1559,"briefTitle":1560,"status":272,"phases":1561,"primaryCompletion":274,"completion":274,"start":941,"enrollment":31,"conditions":1562,"interventions":1564},"NCT02640313","Molecular Imaging of Plaque Vulnerability",[89],[1563],"Plaque, Atherosclerotic",[1548],{"trials":1566,"activeCount":98},[],{"trials":1568,"activeCount":98},[],{"intervention":1570,"totalTrials":94,"cells":1571},"Imiquimod 5% cream with prior curettage",{"EARLY_PHASE1":1572,"PHASE1":1574,"PHASE2":1576,"PHASE3":1578,"PHASE4":1591,"NA":1593},{"trials":1573,"activeCount":98},[],{"trials":1575,"activeCount":98},[],{"trials":1577,"activeCount":98},[],{"trials":1579,"activeCount":98},[1580],{"nctId":1581,"briefTitle":1582,"status":272,"phases":1583,"primaryCompletion":1584,"completion":1585,"start":1586,"enrollment":1587,"conditions":1588,"interventions":1590},"NCT02242929","Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma",[89],"2017-12","2022-12","2016-01",145,[1589],"Nodular Basal Cell Carcinoma",[1570],{"trials":1592,"activeCount":98},[],{"trials":1594,"activeCount":98},[],{"intervention":1596,"totalTrials":94,"cells":1597},"Adenosine 5'-triphosphate",{"EARLY_PHASE1":1598,"PHASE1":1600,"PHASE2":1602,"PHASE3":1604,"PHASE4":1619,"NA":1621},{"trials":1599,"activeCount":98},[],{"trials":1601,"activeCount":98},[],{"trials":1603,"activeCount":98},[],{"trials":1605,"activeCount":98},[1606],{"nctId":1607,"briefTitle":1608,"status":544,"phases":1609,"completion":1610,"start":1611,"enrollment":1612,"conditions":1613,"interventions":1618},"NCT00565188","Application of ATP Infusions in Palliative Home Care",[89],"2006-10","2002-03",100,[1614,1615,1616,1617],"Cancer","Palliative Care","Survival","Quality of Life",[1596],{"trials":1620,"activeCount":98},[],{"trials":1622,"activeCount":98},[],{"intervention":1624,"totalTrials":94,"cells":1625},"Bromfenac",{"EARLY_PHASE1":1626,"PHASE1":1628,"PHASE2":1630,"PHASE3":1632,"PHASE4":1649,"NA":1651},{"trials":1627,"activeCount":98},[],{"trials":1629,"activeCount":98},[],{"trials":1631,"activeCount":98},[],{"trials":1633,"activeCount":98},[1634],{"nctId":1635,"briefTitle":1636,"status":544,"phases":1637,"primaryCompletion":1638,"completion":1638,"start":1639,"enrollment":1640,"conditions":1641,"interventions":1645},"NCT01774474","PRevention of Macular EDema After Cataract Surgery",[89],"2016-11-04","2013-07-10",1127,[1642,1643,1644],"Cystoid Macular Edema","Cataract","Diabetes Mellitus",[1624,1646,1647,1648],"Dexamethasone","Bevacizumab","Triamcinolone Acetonide",{"trials":1650,"activeCount":98},[],{"trials":1652,"activeCount":98},[],{"intervention":1646,"totalTrials":94,"cells":1654},{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1659,"PHASE3":1661,"PHASE4":1667,"NA":1669},{"trials":1656,"activeCount":98},[],{"trials":1658,"activeCount":98},[],{"trials":1660,"activeCount":98},[],{"trials":1662,"activeCount":98},[1663],{"nctId":1635,"briefTitle":1636,"status":544,"phases":1664,"primaryCompletion":1638,"completion":1638,"start":1639,"enrollment":1640,"conditions":1665,"interventions":1666},[89],[1642,1643,1644],[1624,1646,1647,1648],{"trials":1668,"activeCount":98},[],{"trials":1670,"activeCount":98},[],{"intervention":1647,"totalTrials":94,"cells":1672},{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1679,"PHASE4":1685,"NA":1687},{"trials":1674,"activeCount":98},[],{"trials":1676,"activeCount":98},[],{"trials":1678,"activeCount":98},[],{"trials":1680,"activeCount":98},[1681],{"nctId":1635,"briefTitle":1636,"status":544,"phases":1682,"primaryCompletion":1638,"completion":1638,"start":1639,"enrollment":1640,"conditions":1683,"interventions":1684},[89],[1642,1643,1644],[1624,1646,1647,1648],{"trials":1686,"activeCount":98},[],{"trials":1688,"activeCount":98},[],{"intervention":1648,"totalTrials":94,"cells":1690},{"EARLY_PHASE1":1691,"PHASE1":1693,"PHASE2":1695,"PHASE3":1697,"PHASE4":1703,"NA":1705},{"trials":1692,"activeCount":98},[],{"trials":1694,"activeCount":98},[],{"trials":1696,"activeCount":98},[],{"trials":1698,"activeCount":98},[1699],{"nctId":1635,"briefTitle":1636,"status":544,"phases":1700,"primaryCompletion":1638,"completion":1638,"start":1639,"enrollment":1640,"conditions":1701,"interventions":1702},[89],[1642,1643,1644],[1624,1646,1647,1648],{"trials":1704,"activeCount":98},[],{"trials":1706,"activeCount":98},[],{"intervention":1708,"totalTrials":94,"cells":1709},"Anastrozole",{"EARLY_PHASE1":1710,"PHASE1":1712,"PHASE2":1714,"PHASE3":1716,"PHASE4":1727,"NA":1729},{"trials":1711,"activeCount":98},[],{"trials":1713,"activeCount":98},[],{"trials":1715,"activeCount":98},[],{"trials":1717,"activeCount":98},[1718],{"nctId":1719,"briefTitle":1720,"status":544,"phases":1721,"primaryCompletion":1722,"completion":1722,"start":1723,"enrollment":1724,"conditions":1725,"interventions":1726},"NCT00301457","Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer",[89],"2022-04","2006-06",1914,[20],[1708],{"trials":1728,"activeCount":98},[],{"trials":1730,"activeCount":98},[],{"intervention":1732,"totalTrials":94,"cells":1733},"standard anaesthesia",{"EARLY_PHASE1":1734,"PHASE1":1736,"PHASE2":1738,"PHASE3":1740,"PHASE4":1752,"NA":1754},{"trials":1735,"activeCount":98},[],{"trials":1737,"activeCount":98},[],{"trials":1739,"activeCount":98},[],{"trials":1741,"activeCount":98},[1742],{"nctId":1743,"briefTitle":1744,"status":544,"phases":1745,"primaryCompletion":1746,"completion":1008,"start":1610,"enrollment":1747,"conditions":1748,"interventions":1749},"NCT00547989","Paravertebral Block, an Adjunct to General Anaesthesia for Breast Surgery?",[89],"2010-12",46,[20],[1732,1750,1751],"additional pvb (ropivacaine) and elastomeric disposable infusion pump","additional pvb",{"trials":1753,"activeCount":98},[],{"trials":1755,"activeCount":98},[],{"intervention":1750,"totalTrials":94,"cells":1757},{"EARLY_PHASE1":1758,"PHASE1":1760,"PHASE2":1762,"PHASE3":1764,"PHASE4":1770,"NA":1772},{"trials":1759,"activeCount":98},[],{"trials":1761,"activeCount":98},[],{"trials":1763,"activeCount":98},[],{"trials":1765,"activeCount":98},[1766],{"nctId":1743,"briefTitle":1744,"status":544,"phases":1767,"primaryCompletion":1746,"completion":1008,"start":1610,"enrollment":1747,"conditions":1768,"interventions":1769},[89],[20],[1732,1750,1751],{"trials":1771,"activeCount":98},[],{"trials":1773,"activeCount":98},[],{"intervention":1751,"totalTrials":94,"cells":1775},{"EARLY_PHASE1":1776,"PHASE1":1778,"PHASE2":1780,"PHASE3":1782,"PHASE4":1788,"NA":1790},{"trials":1777,"activeCount":98},[],{"trials":1779,"activeCount":98},[],{"trials":1781,"activeCount":98},[],{"trials":1783,"activeCount":98},[1784],{"nctId":1743,"briefTitle":1744,"status":544,"phases":1785,"primaryCompletion":1746,"completion":1008,"start":1610,"enrollment":1747,"conditions":1786,"interventions":1787},[89],[20],[1732,1750,1751],{"trials":1789,"activeCount":98},[],{"trials":1791,"activeCount":98},[],{"intervention":1793,"totalTrials":94,"cells":1794},"Rapamycin",{"EARLY_PHASE1":1795,"PHASE1":1797,"PHASE2":1799,"PHASE3":1801,"PHASE4":1812,"NA":1814},{"trials":1796,"activeCount":98},[],{"trials":1798,"activeCount":98},[],{"trials":1800,"activeCount":98},[],{"trials":1802,"activeCount":98},[1803],{"nctId":1804,"briefTitle":1805,"status":544,"phases":1806,"primaryCompletion":1807,"completion":749,"start":1808,"enrollment":11,"conditions":1809,"interventions":1811},"NCT00928798","Topical Rapamycin for Fibrofolliculomas",[89],"2011-02","2010-01",[1810],"Birt-Hogg-Dubé Syndrome",[1793],{"trials":1813,"activeCount":98},[],{"trials":1815,"activeCount":98},[],{"intervention":1817,"totalTrials":94,"cells":1818},"Ileocolonic release peppermint oil",{"EARLY_PHASE1":1819,"PHASE1":1821,"PHASE2":1823,"PHASE3":1825,"PHASE4":1840,"NA":1842},{"trials":1820,"activeCount":98},[],{"trials":1822,"activeCount":98},[],{"trials":1824,"activeCount":98},[],{"trials":1826,"activeCount":98},[1827],{"nctId":1828,"briefTitle":1829,"status":544,"phases":1830,"primaryCompletion":1831,"completion":1832,"start":1833,"enrollment":1834,"conditions":1835,"interventions":1838},"NCT02716285","Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery",[89],"2018-05-01","2018-10-01","2016-08-17",190,[869,1836,1837],"Abdominal Pain","Colonic Diseases, Functional",[1817,1839],"Small intestinal release peppermint oil",{"trials":1841,"activeCount":98},[],{"trials":1843,"activeCount":98},[],{"intervention":1839,"totalTrials":94,"cells":1845},{"EARLY_PHASE1":1846,"PHASE1":1848,"PHASE2":1850,"PHASE3":1852,"PHASE4":1858,"NA":1860},{"trials":1847,"activeCount":98},[],{"trials":1849,"activeCount":98},[],{"trials":1851,"activeCount":98},[],{"trials":1853,"activeCount":98},[1854],{"nctId":1828,"briefTitle":1829,"status":544,"phases":1855,"primaryCompletion":1831,"completion":1832,"start":1833,"enrollment":1834,"conditions":1856,"interventions":1857},[89],[869,1836,1837],[1817,1839],{"trials":1859,"activeCount":98},[],{"trials":1861,"activeCount":98},[],{"intervention":1863,"totalTrials":94,"cells":1864},"Antioxidant",{"EARLY_PHASE1":1865,"PHASE1":1867,"PHASE2":1869,"PHASE3":1871,"PHASE4":1883,"NA":1885},{"trials":1866,"activeCount":98},[],{"trials":1868,"activeCount":98},[],{"trials":1870,"activeCount":98},[],{"trials":1872,"activeCount":98},[1873],{"nctId":1874,"briefTitle":1875,"status":272,"phases":1876,"primaryCompletion":1807,"start":1877,"enrollment":1878,"conditions":1879,"interventions":1881},"NCT00821158","The DIEP Flap as a Model of Ischemia-Reperfusion: an Intervention Study",[89],"2009-02",30,[1880],"Ischemia-Reperfusion",[1863,1882],"Anti-inflammatory drug",{"trials":1884,"activeCount":98},[],{"trials":1886,"activeCount":98},[],{"intervention":1882,"totalTrials":94,"cells":1888},{"EARLY_PHASE1":1889,"PHASE1":1891,"PHASE2":1893,"PHASE3":1895,"PHASE4":1901,"NA":1903},{"trials":1890,"activeCount":98},[],{"trials":1892,"activeCount":98},[],{"trials":1894,"activeCount":98},[],{"trials":1896,"activeCount":98},[1897],{"nctId":1874,"briefTitle":1875,"status":272,"phases":1898,"primaryCompletion":1807,"start":1877,"enrollment":1878,"conditions":1899,"interventions":1900},[89],[1880],[1863,1882],{"trials":1902,"activeCount":98},[],{"trials":1904,"activeCount":98},[],{"intervention":1906,"totalTrials":94,"cells":1907},"Sinecatechins 10%",{"EARLY_PHASE1":1908,"PHASE1":1910,"PHASE2":1912,"PHASE3":1914,"PHASE4":1924,"NA":1926},{"trials":1909,"activeCount":98},[],{"trials":1911,"activeCount":98},[],{"trials":1913,"activeCount":98},[],{"trials":1915,"activeCount":98},[1916],{"nctId":1917,"briefTitle":1918,"status":544,"phases":1919,"primaryCompletion":589,"completion":1920,"start":821,"enrollment":1921,"conditions":1922,"interventions":1923},"NCT02029352","Topical Green Tea Ointment in Treatment of Superficial Skin Cancer",[88,89],"2016-02",42,[506],[1906],{"trials":1925,"activeCount":98},[],{"trials":1927,"activeCount":98},[],{"intervention":1929,"totalTrials":94,"cells":1930},"Nortriptyline",{"EARLY_PHASE1":1931,"PHASE1":1933,"PHASE2":1935,"PHASE3":1937,"PHASE4":1949,"NA":1951},{"trials":1932,"activeCount":98},[],{"trials":1934,"activeCount":98},[],{"trials":1936,"activeCount":98},[],{"trials":1938,"activeCount":98},[1939],{"nctId":1940,"briefTitle":1941,"status":676,"phases":1942,"primaryCompletion":1943,"completion":1943,"start":1944,"enrollment":1945,"conditions":1946,"interventions":1948},"NCT03652571","Nortriptyline for the Treatment of Functional Dyspepsia",[89],"2024-08-01","2018-09-01",96,[1947],"Functional Dyspepsia",[1929],{"trials":1950,"activeCount":98},[],{"trials":1952,"activeCount":98},[],{"intervention":1954,"totalTrials":94,"cells":1955},"Extended-release Guanfacine Hydrochloride",{"EARLY_PHASE1":1956,"PHASE1":1958,"PHASE2":1960,"PHASE3":1962,"PHASE4":1974,"NA":1976},{"trials":1957,"activeCount":98},[],{"trials":1959,"activeCount":98},[],{"trials":1961,"activeCount":98},[],{"trials":1963,"activeCount":98},[1964],{"nctId":1965,"briefTitle":1966,"status":544,"phases":1967,"primaryCompletion":1051,"completion":1968,"start":1969,"enrollment":1970,"conditions":1971,"interventions":1973},"NCT03662763","Extended-release Guanfacine Hydrochloride in Children\u002FAdolescents With Attention-deficit\u002FHyperactivity",[89],"2013-12","2011-09",12,[1972],"Attention Deficit Disorder",[1954],{"trials":1975,"activeCount":98},[],{"trials":1977,"activeCount":98},[],{"intervention":1979,"totalTrials":248,"cells":1980},"Roflumilast",{"EARLY_PHASE1":1981,"PHASE1":1983,"PHASE2":1985,"PHASE3":2007,"PHASE4":2009,"NA":2011},{"trials":1982,"activeCount":98},[],{"trials":1984,"activeCount":98},[],{"trials":1986,"activeCount":98},[1987,1998],{"nctId":1988,"briefTitle":1989,"status":272,"phases":1990,"primaryCompletion":1991,"completion":1991,"start":1992,"enrollment":1993,"conditions":1994,"interventions":1997},"NCT04658654","Cognitive Effects of Roflumilast in (a)MCI and Mild Dementia Patients",[88],"2023-10","2021-11-19",81,[943,1995,1996],"Mild Dementia","Amnestic Mild Cognitive Disorder",[1979],{"nctId":1999,"briefTitle":2000,"status":544,"phases":2001,"primaryCompletion":1166,"completion":2002,"start":1969,"enrollment":966,"conditions":2003,"interventions":2005},"NCT01433666","Roflumilast and Cognition",[88],"2013-09",[2004],"Dementia",[2006,2006],"roflumilast",{"trials":2008,"activeCount":98},[],{"trials":2010,"activeCount":98},[],{"trials":2012,"activeCount":98},[],{"intervention":2014,"totalTrials":248,"cells":2015},"HBVaxPro",{"EARLY_PHASE1":2016,"PHASE1":2018,"PHASE2":2030,"PHASE3":2041,"PHASE4":2043,"NA":2045},{"trials":2017,"activeCount":98},[],{"trials":2019,"activeCount":98},[2020],{"nctId":2021,"briefTitle":2022,"status":544,"phases":2023,"primaryCompletion":2024,"completion":2024,"start":589,"enrollment":2025,"conditions":2026,"interventions":2028},"NCT02540538","Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders",[87],"2016-07",34,[2027],"Hepatitis B",[2014,2029],"HBAI20",{"trials":2031,"activeCount":98},[2032],{"nctId":2033,"briefTitle":2034,"status":544,"phases":2035,"primaryCompletion":2036,"completion":2036,"start":2037,"enrollment":2038,"conditions":2039,"interventions":2040},"NCT03415672","Hepatitis B Vaccine for Non-responders",[88],"2019-01-09","2017-10-11",133,[2027],[2014,2029],{"trials":2042,"activeCount":98},[],{"trials":2044,"activeCount":98},[],{"trials":2046,"activeCount":98},[],{"intervention":2029,"totalTrials":248,"cells":2048},{"EARLY_PHASE1":2049,"PHASE1":2051,"PHASE2":2057,"PHASE3":2063,"PHASE4":2065,"NA":2067},{"trials":2050,"activeCount":98},[],{"trials":2052,"activeCount":98},[2053],{"nctId":2021,"briefTitle":2022,"status":544,"phases":2054,"primaryCompletion":2024,"completion":2024,"start":589,"enrollment":2025,"conditions":2055,"interventions":2056},[87],[2027],[2014,2029],{"trials":2058,"activeCount":98},[2059],{"nctId":2033,"briefTitle":2034,"status":544,"phases":2060,"primaryCompletion":2036,"completion":2036,"start":2037,"enrollment":2038,"conditions":2061,"interventions":2062},[88],[2027],[2014,2029],{"trials":2064,"activeCount":98},[],{"trials":2066,"activeCount":98},[],{"trials":2068,"activeCount":98},[],{"intervention":553,"totalTrials":94,"cells":2070},{"EARLY_PHASE1":2071,"PHASE1":2073,"PHASE2":2075,"PHASE3":2081,"PHASE4":2083,"NA":2085},{"trials":2072,"activeCount":98},[],{"trials":2074,"activeCount":98},[],{"trials":2076,"activeCount":98},[2077],{"nctId":542,"briefTitle":543,"status":544,"phases":2078,"primaryCompletion":546,"completion":546,"start":547,"enrollment":548,"conditions":2079,"interventions":2080},[88],[550,551],[553,533],{"trials":2082,"activeCount":98},[],{"trials":2084,"activeCount":98},[],{"trials":2086,"activeCount":98},[],{"intervention":2088,"totalTrials":94,"cells":2089},"Diclofenac",{"EARLY_PHASE1":2090,"PHASE1":2092,"PHASE2":2094,"PHASE3":2108,"PHASE4":2110,"NA":2112},{"trials":2091,"activeCount":98},[],{"trials":2093,"activeCount":98},[],{"trials":2095,"activeCount":98},[2096],{"nctId":2097,"briefTitle":2098,"status":544,"phases":2099,"primaryCompletion":2100,"completion":2101,"start":2102,"enrollment":2103,"conditions":2104,"interventions":2105},"NCT01358045","Topical Vitamin D3, Diclofenac or a Combination of Both to Treat Basal Cell Carcinoma",[88],"2013-02","2013-05","2011-11",128,[501],[2088,2106,2107],"Diclofenac + Calcitriol","Calcitriol",{"trials":2109,"activeCount":98},[],{"trials":2111,"activeCount":98},[],{"trials":2113,"activeCount":98},[],{"intervention":2106,"totalTrials":94,"cells":2115},{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2120,"PHASE3":2126,"PHASE4":2128,"NA":2130},{"trials":2117,"activeCount":98},[],{"trials":2119,"activeCount":98},[],{"trials":2121,"activeCount":98},[2122],{"nctId":2097,"briefTitle":2098,"status":544,"phases":2123,"primaryCompletion":2100,"completion":2101,"start":2102,"enrollment":2103,"conditions":2124,"interventions":2125},[88],[501],[2088,2106,2107],{"trials":2127,"activeCount":98},[],{"trials":2129,"activeCount":98},[],{"trials":2131,"activeCount":98},[],{"intervention":2107,"totalTrials":94,"cells":2133},{"EARLY_PHASE1":2134,"PHASE1":2136,"PHASE2":2138,"PHASE3":2144,"PHASE4":2146,"NA":2148},{"trials":2135,"activeCount":98},[],{"trials":2137,"activeCount":98},[],{"trials":2139,"activeCount":98},[2140],{"nctId":2097,"briefTitle":2098,"status":544,"phases":2141,"primaryCompletion":2100,"completion":2101,"start":2102,"enrollment":2103,"conditions":2142,"interventions":2143},[88],[501],[2088,2106,2107],{"trials":2145,"activeCount":98},[],{"trials":2147,"activeCount":98},[],{"trials":2149,"activeCount":98},[],{"intervention":2151,"totalTrials":94,"cells":2152},"Darleukin",{"EARLY_PHASE1":2153,"PHASE1":2155,"PHASE2":2157,"PHASE3":2169,"PHASE4":2171,"NA":2173},{"trials":2154,"activeCount":98},[],{"trials":2156,"activeCount":98},[],{"trials":2158,"activeCount":98},[2159],{"nctId":2160,"briefTitle":2161,"status":676,"phases":2162,"primaryCompletion":2163,"completion":2163,"start":2164,"enrollment":2165,"conditions":2166,"interventions":2168},"NCT03705403","IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study",[88],"2025-01-06","2019-04-04",88,[294,2167],"Metastatic Disease",[2151],{"trials":2170,"activeCount":98},[],{"trials":2172,"activeCount":98},[],{"trials":2174,"activeCount":98},[],{"intervention":2176,"totalTrials":94,"cells":2177},"celecoxib",{"EARLY_PHASE1":2178,"PHASE1":2180,"PHASE2":2182,"PHASE3":2192,"PHASE4":2194,"NA":2196},{"trials":2179,"activeCount":98},[],{"trials":2181,"activeCount":98},[],{"trials":2183,"activeCount":98},[2184],{"nctId":2185,"briefTitle":2186,"status":544,"phases":2187,"primaryCompletion":1413,"start":2188,"conditions":2189,"interventions":2191},"NCT01695226","Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer",[88],"2004-02",[2190,20],"Breast Neoplasms",[2176],{"trials":2193,"activeCount":98},[],{"trials":2195,"activeCount":98},[],{"trials":2197,"activeCount":98},[],{"intervention":2199,"totalTrials":94,"cells":2200},"vaccination with Nicvax",{"EARLY_PHASE1":2201,"PHASE1":2203,"PHASE2":2205,"PHASE3":2217,"PHASE4":2219,"NA":2221},{"trials":2202,"activeCount":98},[],{"trials":2204,"activeCount":98},[],{"trials":2206,"activeCount":98},[2207],{"nctId":2208,"briefTitle":2209,"status":544,"phases":2210,"primaryCompletion":2211,"completion":2211,"start":1807,"enrollment":2212,"conditions":2213,"interventions":2216},"NCT01318668","A Fmri Study on the Effects of a Conjugate Vaccine and Placebo on CNS Activation and Behavior Following a Nicotine Challenge",[87,88],"2012-06",38,[2214,2215],"Nicotine Dependency","Smoking",[2199],{"trials":2218,"activeCount":98},[],{"trials":2220,"activeCount":98},[],{"trials":2222,"activeCount":98},[],{"intervention":2224,"totalTrials":94,"cells":2225},"Ketohexokinase inhibition",{"EARLY_PHASE1":2226,"PHASE1":2228,"PHASE2":2230,"PHASE3":2241,"PHASE4":2243,"NA":2245},{"trials":2227,"activeCount":98},[],{"trials":2229,"activeCount":98},[],{"trials":2231,"activeCount":98},[2232],{"nctId":2233,"briefTitle":2234,"status":544,"phases":2235,"primaryCompletion":2236,"completion":2236,"start":2237,"enrollment":26,"conditions":2238,"interventions":2240},"NCT05463575","Ketohexokinase Inhibition in NAFLD",[88],"2023-11-24","2022-10-01",[2239],"NAFLD",[2224],{"trials":2242,"activeCount":98},[],{"trials":2244,"activeCount":98},[],{"trials":2246,"activeCount":98},[],{"intervention":2248,"totalTrials":94,"cells":2249},"PF-06801591",{"EARLY_PHASE1":2250,"PHASE1":2252,"PHASE2":2254,"PHASE3":2265,"PHASE4":2267,"NA":2269},{"trials":2251,"activeCount":98},[],{"trials":2253,"activeCount":98},[],{"trials":2255,"activeCount":98},[2256],{"nctId":2257,"briefTitle":2258,"status":544,"phases":2259,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":775,"conditions":2262,"interventions":2264},"NCT06089265","Ketohexokinase Inhibition in Hereditary Fructose Intolerance",[88],"2023-11-30","2023-06-15",[2263],"HFI",[2248],{"trials":2266,"activeCount":98},[],{"trials":2268,"activeCount":98},[],{"trials":2270,"activeCount":98},[],{"intervention":2272,"totalTrials":94,"cells":2273},"NicVAX vaccine",{"EARLY_PHASE1":2274,"PHASE1":2276,"PHASE2":2278,"PHASE3":2293,"PHASE4":2295,"NA":2297},{"trials":2275,"activeCount":98},[],{"trials":2277,"activeCount":98},[],{"trials":2279,"activeCount":98},[2280],{"nctId":2281,"briefTitle":2282,"status":544,"phases":2283,"primaryCompletion":2284,"completion":2284,"start":2285,"enrollment":2286,"conditions":2287,"interventions":2291},"NCT00995033","Efficacy and Safety of NicVAX® Co-administered With Varenicline (Champix®)",[88],"2012-09","2009-10",558,[2288,2289,2290],"Smoking Behavior","Smoking Lapse Behavior","Smoking Relapse Behavior",[2272,2292],"Varenicline",{"trials":2294,"activeCount":98},[],{"trials":2296,"activeCount":98},[],{"trials":2298,"activeCount":98},[],{"intervention":2292,"totalTrials":94,"cells":2300},{"EARLY_PHASE1":2301,"PHASE1":2303,"PHASE2":2305,"PHASE3":2311,"PHASE4":2313,"NA":2315},{"trials":2302,"activeCount":98},[],{"trials":2304,"activeCount":98},[],{"trials":2306,"activeCount":98},[2307],{"nctId":2281,"briefTitle":2282,"status":544,"phases":2308,"primaryCompletion":2284,"completion":2284,"start":2285,"enrollment":2286,"conditions":2309,"interventions":2310},[88],[2288,2289,2290],[2272,2292],{"trials":2312,"activeCount":98},[],{"trials":2314,"activeCount":98},[],{"trials":2316,"activeCount":98},[],{"intervention":2318,"totalTrials":94,"cells":2319},"Menthae piperitae aetheroleum\u002Fpeppermint oil",{"EARLY_PHASE1":2320,"PHASE1":2322,"PHASE2":2324,"PHASE3":2335,"PHASE4":2337,"NA":2339},{"trials":2321,"activeCount":98},[],{"trials":2323,"activeCount":98},[],{"trials":2325,"activeCount":98},[2326],{"nctId":2327,"briefTitle":2328,"status":544,"phases":2329,"primaryCompletion":1007,"completion":589,"start":2330,"enrollment":775,"conditions":2331,"interventions":2334},"NCT02291445","Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®), a Pharmacokinetic Study",[88],"2015-03",[869,1836,2332,2333],"Colonic Diseases","Visceral Pain",[2318,2318],{"trials":2336,"activeCount":98},[],{"trials":2338,"activeCount":98},[],{"trials":2340,"activeCount":98},[],{"intervention":2342,"totalTrials":94,"cells":2343},"JDQ443",{"EARLY_PHASE1":2344,"PHASE1":2346,"PHASE2":2348,"PHASE3":2361,"PHASE4":2363,"NA":2365},{"trials":2345,"activeCount":98},[],{"trials":2347,"activeCount":98},[],{"trials":2349,"activeCount":98},[2350],{"nctId":2351,"briefTitle":2352,"status":917,"phases":2353,"primaryCompletion":2354,"completion":2355,"start":2356,"enrollment":98,"conditions":2357,"interventions":2360},"NCT05999357","JDQ443 for KRAS G12C NSCLC Brain Metastases",[88],"2027-08","2028-08","2024-04-15",[2358,295,2359],"Non Small Cell Lung Cancer Metastatic","KRAS G12C",[2342],{"trials":2362,"activeCount":98},[],{"trials":2364,"activeCount":98},[],{"trials":2366,"activeCount":98},[],{"intervention":2368,"totalTrials":94,"cells":2369},"Tacrolimus",{"EARLY_PHASE1":2370,"PHASE1":2372,"PHASE2":2383,"PHASE3":2385,"PHASE4":2387,"NA":2389},{"trials":2371,"activeCount":98},[],{"trials":2373,"activeCount":98},[2374],{"nctId":2375,"briefTitle":2376,"status":272,"phases":2377,"primaryCompletion":1969,"completion":1969,"start":2378,"enrollment":2379,"conditions":2380,"interventions":2382},"NCT00987103","Pharmacokinetic Study to Rectal and Sublingual Administration of Tacrolimus in Future Kidney Transplant Patients",[87],"2009-09",18,[2381],"Organ Transplantation",[2368],{"trials":2384,"activeCount":98},[],{"trials":2386,"activeCount":98},[],{"trials":2388,"activeCount":98},[],{"trials":2390,"activeCount":98},[],{"intervention":2392,"totalTrials":94,"cells":2393},"Intravenous immunoglobulin therapy",{"EARLY_PHASE1":2394,"PHASE1":2396,"PHASE2":2407,"PHASE3":2409,"PHASE4":2411,"NA":2413},{"trials":2395,"activeCount":98},[],{"trials":2397,"activeCount":98},[2398],{"nctId":2399,"briefTitle":2400,"status":272,"phases":2401,"primaryCompletion":2402,"completion":2403,"start":1877,"enrollment":455,"conditions":2404,"interventions":2406},"NCT00659386","IVIg Therapy for Patients With Idiopathic Cardiomyopathy and Endomyocardial Biopsy Proven High PVB19 Viral Load",[87],"2010-02","2010-08",[2405],"Heart Failure",[2392],{"trials":2408,"activeCount":98},[],{"trials":2410,"activeCount":98},[],{"trials":2412,"activeCount":98},[],{"trials":2414,"activeCount":98},[],{"intervention":2416,"totalTrials":94,"cells":2417},"indometacin",{"EARLY_PHASE1":2418,"PHASE1":2428,"PHASE2":2430,"PHASE3":2432,"PHASE4":2434,"NA":2436},{"trials":2419,"activeCount":98},[2420],{"nctId":2421,"briefTitle":2422,"status":272,"phases":2423,"primaryCompletion":2424,"completion":2424,"start":2378,"enrollment":2025,"conditions":2425,"interventions":2427},"NCT00943345","Validation of New Tests for Gastrointestinal (GI) Permeability",[86],"2012-02",[2426],"Gastrointestinal Diseases",[2416],{"trials":2429,"activeCount":98},[],{"trials":2431,"activeCount":98},[],{"trials":2433,"activeCount":98},[],{"trials":2435,"activeCount":98},[],{"trials":2437,"activeCount":98},[],{"intervention":2439,"totalTrials":94,"cells":2440},"Pilocarpine Ophthalmic Solution",{"EARLY_PHASE1":2441,"PHASE1":2453,"PHASE2":2455,"PHASE3":2457,"PHASE4":2459,"NA":2461},{"trials":2442,"activeCount":98},[2443],{"nctId":2444,"briefTitle":2445,"status":544,"phases":2446,"primaryCompletion":2447,"completion":2448,"start":2449,"enrollment":31,"conditions":2450,"interventions":2452},"NCT04195100","Local Pilocarpine for Relieving Dry Mouth",[86],"2019-12-01","2020-01-31","2019-04-01",[2451],"Patients of Advanced Age (≥ 70 Years) With a Clinical Diagnosis of Chronic Dry Mouth",[2439],{"trials":2454,"activeCount":98},[],{"trials":2456,"activeCount":98},[],{"trials":2458,"activeCount":98},[],{"trials":2460,"activeCount":98},[],{"trials":2462,"activeCount":98},[],{"intervention":826,"totalTrials":2464,"cells":2465},3,{"EARLY_PHASE1":2466,"PHASE1":2468,"PHASE2":2470,"PHASE3":2472,"PHASE4":2483,"NA":2489},{"trials":2467,"activeCount":98},[],{"trials":2469,"activeCount":98},[],{"trials":2471,"activeCount":98},[],{"trials":2473,"activeCount":98},[2474],{"nctId":2475,"briefTitle":2476,"status":676,"phases":2477,"primaryCompletion":2478,"completion":2478,"start":652,"enrollment":2479,"conditions":2480,"interventions":2482},"NCT02329171","Imiquimod Treatment of CIN Lesions",[89],"2016-06",9,[2481],"Cervical Intraepithelial Neoplasia",[826],{"trials":2484,"activeCount":98},[2485],{"nctId":816,"briefTitle":817,"status":272,"phases":2486,"primaryCompletion":819,"completion":820,"start":821,"enrollment":822,"conditions":2487,"interventions":2488},[90],[824],[826,803,827],{"trials":2490,"activeCount":98},[2491],{"nctId":2492,"briefTitle":2493,"status":272,"phases":2494,"primaryCompletion":819,"completion":704,"start":2495,"enrollment":1515,"conditions":2496,"interventions":2497},"NCT02917746","Imiquimod Treatment of High-grade CIN",[91],"2016-11",[2481],[826],{"intervention":2499,"totalTrials":248,"cells":2500},"Influenza vaccine",{"EARLY_PHASE1":2501,"PHASE1":2503,"PHASE2":2505,"PHASE3":2507,"PHASE4":2509,"NA":2511},{"trials":2502,"activeCount":98},[],{"trials":2504,"activeCount":98},[],{"trials":2506,"activeCount":98},[],{"trials":2508,"activeCount":98},[],{"trials":2510,"activeCount":98},[],{"trials":2512,"activeCount":98},[2513,2523],{"nctId":2514,"briefTitle":2515,"status":544,"phases":2516,"primaryCompletion":2517,"completion":2517,"start":2518,"enrollment":2519,"conditions":2520,"interventions":2522},"NCT05706350","Plant Stanol Esters and Influenza Vaccination",[91],"2022-12-20","2022-10-11",137,[2521],"Immune Response",[2499],{"nctId":2524,"briefTitle":2525,"status":544,"phases":2526,"primaryCompletion":2527,"completion":2528,"start":2529,"enrollment":2165,"conditions":2530,"interventions":2531},"NCT06041867","Agaricus Bisporus and Influenza Vaccination Response",[91],"2023-12-15","2024-05-30","2023-09-14",[2521],[2499],{"intervention":2533,"totalTrials":248,"cells":2534},"Amoxicillin",{"EARLY_PHASE1":2535,"PHASE1":2537,"PHASE2":2539,"PHASE3":2541,"PHASE4":2543,"NA":2545},{"trials":2536,"activeCount":98},[],{"trials":2538,"activeCount":98},[],{"trials":2540,"activeCount":98},[],{"trials":2542,"activeCount":98},[],{"trials":2544,"activeCount":98},[],{"trials":2546,"activeCount":98},[2547,2557],{"nctId":2548,"briefTitle":2549,"status":544,"phases":2550,"primaryCompletion":2551,"completion":2551,"start":2552,"enrollment":2553,"conditions":2554,"interventions":2556},"NCT01566266","Gut Flora and Lipid Metabolism",[91],"2013-04","2012-03",77,[2555],"Hypercholesterolemia",[2533],{"nctId":2558,"briefTitle":2559,"status":544,"phases":2560,"primaryCompletion":1165,"completion":821,"start":2561,"enrollment":2562,"conditions":2563,"interventions":2564},"NCT02241421","The Importance of the Gut Microbiota in Body Weight Control and Insulin Sensitivity",[91],"2012-04",57,[15,23],[2533,2565],"Vancomycin",{"intervention":2567,"totalTrials":94,"cells":2568},"cetirizine 10 mg",{"EARLY_PHASE1":2569,"PHASE1":2571,"PHASE2":2573,"PHASE3":2575,"PHASE4":2577,"NA":2579},{"trials":2570,"activeCount":98},[],{"trials":2572,"activeCount":98},[],{"trials":2574,"activeCount":98},[],{"trials":2576,"activeCount":98},[],{"trials":2578,"activeCount":98},[],{"trials":2580,"activeCount":98},[2581],{"nctId":2582,"briefTitle":2583,"status":544,"phases":2584,"primaryCompletion":2552,"completion":965,"start":2585,"enrollment":966,"conditions":2586,"interventions":2590},"NCT01318681","Rhinitis, Cognition and Driving Performance",[91],"2011-01",[2587,2588,2589],"Seasonal Allergic Rhinitis","Driving Ability","Cognition",[2567,2591],"fluticasone furoate",{"intervention":2591,"totalTrials":94,"cells":2593},{"EARLY_PHASE1":2594,"PHASE1":2596,"PHASE2":2598,"PHASE3":2600,"PHASE4":2602,"NA":2604},{"trials":2595,"activeCount":98},[],{"trials":2597,"activeCount":98},[],{"trials":2599,"activeCount":98},[],{"trials":2601,"activeCount":98},[],{"trials":2603,"activeCount":98},[],{"trials":2605,"activeCount":98},[2606],{"nctId":2582,"briefTitle":2583,"status":544,"phases":2607,"primaryCompletion":2552,"completion":965,"start":2585,"enrollment":966,"conditions":2608,"interventions":2609},[91],[2587,2588,2589],[2567,2591],{"intervention":2611,"totalTrials":94,"cells":2612},"Ropivacaine\u002F Sufentanil according to local hospital protocol",{"EARLY_PHASE1":2613,"PHASE1":2615,"PHASE2":2617,"PHASE3":2619,"PHASE4":2621,"NA":2623},{"trials":2614,"activeCount":98},[],{"trials":2616,"activeCount":98},[],{"trials":2618,"activeCount":98},[],{"trials":2620,"activeCount":98},[],{"trials":2622,"activeCount":98},[],{"trials":2624,"activeCount":98},[2625],{"nctId":2626,"briefTitle":2627,"status":544,"phases":2628,"primaryCompletion":964,"completion":964,"start":2629,"enrollment":2630,"conditions":2631,"interventions":2636},"NCT01261689","The Randomised Epidural Analgesia in Term Delivering Women Trial (TREAT)",[91],"2008-09",488,[2632,2633,2634,2635],"Analgesia, Epidural","Instrumental Delivery","Maternal Outcome","Neonatal Outcome",[2611],{"intervention":2638,"totalTrials":94,"cells":2639},"follitropin and lutropin",{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2646,"PHASE4":2648,"NA":2650},{"trials":2641,"activeCount":98},[],{"trials":2643,"activeCount":98},[],{"trials":2645,"activeCount":98},[],{"trials":2647,"activeCount":98},[],{"trials":2649,"activeCount":98},[],{"trials":2651,"activeCount":98},[2652],{"nctId":2653,"briefTitle":2654,"status":272,"phases":2655,"primaryCompletion":2656,"start":2657,"enrollment":9,"conditions":2658,"interventions":2661},"NCT00619333","Inactive FSH in Galactosemia",[91],"2010-03","2007-03",[2659,2660],"Galactosemia","Premature Ovarian Failure",[2638],{"intervention":2663,"totalTrials":94,"cells":2664},"Gadofosveset contrast agent enhanced MRI Axilla",{"EARLY_PHASE1":2665,"PHASE1":2667,"PHASE2":2669,"PHASE3":2671,"PHASE4":2673,"NA":2675},{"trials":2666,"activeCount":98},[],{"trials":2668,"activeCount":98},[],{"trials":2670,"activeCount":98},[],{"trials":2672,"activeCount":98},[],{"trials":2674,"activeCount":98},[],{"trials":2676,"activeCount":98},[2677],{"nctId":2678,"briefTitle":2679,"status":544,"phases":2680,"primaryCompletion":2424,"completion":2552,"start":1969,"enrollment":2681,"conditions":2682,"interventions":2683},"NCT01437865","Gadofosveset for Axillary Staging in Breast Cancer Patients",[91],10,[2190],[2663],{"intervention":2685,"totalTrials":94,"cells":2686},"Trastuzumab",{"EARLY_PHASE1":2687,"PHASE1":2689,"PHASE2":2691,"PHASE3":2693,"PHASE4":2695,"NA":2697},{"trials":2688,"activeCount":98},[],{"trials":2690,"activeCount":98},[],{"trials":2692,"activeCount":98},[],{"trials":2694,"activeCount":98},[],{"trials":2696,"activeCount":98},[],{"trials":2698,"activeCount":98},[2699],{"nctId":2700,"briefTitle":2701,"status":544,"phases":2702,"primaryCompletion":2703,"completion":2101,"start":2704,"enrollment":2705,"conditions":2706,"interventions":2707},"NCT01894711","Real World Efficiency of Trastuzumab in Early Breast Cancer",[],"2012-11","2010-05",2684,[20],[2685],{"intervention":2709,"totalTrials":94,"cells":2710},"Irbesartan",{"EARLY_PHASE1":2711,"PHASE1":2713,"PHASE2":2715,"PHASE3":2717,"PHASE4":2719,"NA":2721},{"trials":2712,"activeCount":98},[],{"trials":2714,"activeCount":98},[],{"trials":2716,"activeCount":98},[],{"trials":2718,"activeCount":98},[],{"trials":2720,"activeCount":98},[],{"trials":2722,"activeCount":98},[2723],{"nctId":2724,"briefTitle":2725,"status":272,"phases":2726,"primaryCompletion":2727,"completion":2727,"start":2728,"enrollment":867,"conditions":2729,"interventions":2731},"NCT00742066","Role of AT1-receptor Blockers in Insulin-induced Vasodilation.",[91],"2009-07","2008-03",[682,23,2730],"Microcirculation",[2709,2732],"Felodipine",{"intervention":2732,"totalTrials":94,"cells":2734},{"EARLY_PHASE1":2735,"PHASE1":2737,"PHASE2":2739,"PHASE3":2741,"PHASE4":2743,"NA":2745},{"trials":2736,"activeCount":98},[],{"trials":2738,"activeCount":98},[],{"trials":2740,"activeCount":98},[],{"trials":2742,"activeCount":98},[],{"trials":2744,"activeCount":98},[],{"trials":2746,"activeCount":98},[2747],{"nctId":2724,"briefTitle":2725,"status":272,"phases":2748,"primaryCompletion":2727,"completion":2727,"start":2728,"enrollment":867,"conditions":2749,"interventions":2750},[91],[682,23,2730],[2709,2732],{"intervention":2752,"totalTrials":94,"cells":2753},"Antihypertensive medication",{"EARLY_PHASE1":2754,"PHASE1":2756,"PHASE2":2758,"PHASE3":2760,"PHASE4":2762,"NA":2764},{"trials":2755,"activeCount":98},[],{"trials":2757,"activeCount":98},[],{"trials":2759,"activeCount":98},[],{"trials":2761,"activeCount":98},[],{"trials":2763,"activeCount":98},[],{"trials":2765,"activeCount":98},[2766],{"nctId":2767,"briefTitle":2768,"status":917,"phases":2769,"primaryCompletion":2770,"completion":2770,"start":476,"enrollment":98,"conditions":2771,"interventions":2774},"NCT02096939","Microvascular Function in Primary Aldosteronism",[],"2016-04",[2772,2773],"Primary Aldosteronism","Essential Hypertension",[2752],{"intervention":2776,"totalTrials":94,"cells":2777},"sulphur hexafluoride, gadopentate dimeglumine",{"EARLY_PHASE1":2778,"PHASE1":2780,"PHASE2":2782,"PHASE3":2784,"PHASE4":2786,"NA":2788},{"trials":2779,"activeCount":98},[],{"trials":2781,"activeCount":98},[],{"trials":2783,"activeCount":98},[],{"trials":2785,"activeCount":98},[],{"trials":2787,"activeCount":98},[],{"trials":2789,"activeCount":98},[2790],{"nctId":2791,"briefTitle":2792,"status":544,"phases":2793,"primaryCompletion":2794,"completion":2794,"start":2795,"enrollment":2379,"conditions":2796,"interventions":2798},"NCT00677963","Contrast-enhanced Ultrasound (CE-US) and Magnetic Resonance Imaging (MRI): Evaluating Plaque Neovascularisation",[91],"2010-04","2009-06",[2797,436],"Carotid Artery Stenosis",[2776],{"intervention":2800,"totalTrials":94,"cells":2801},"Methylphenidate 40 mg",{"EARLY_PHASE1":2802,"PHASE1":2804,"PHASE2":2806,"PHASE3":2808,"PHASE4":2810,"NA":2812},{"trials":2803,"activeCount":98},[],{"trials":2805,"activeCount":98},[],{"trials":2807,"activeCount":98},[],{"trials":2809,"activeCount":98},[],{"trials":2811,"activeCount":98},[],{"trials":2813,"activeCount":98},[2814],{"nctId":2815,"briefTitle":2816,"status":544,"phases":2817,"primaryCompletion":2211,"completion":2211,"start":2818,"enrollment":2819,"conditions":2820,"interventions":2824},"NCT01218425","Dopaminergic Modulation of Cognition and Psychomotor Function",[91],"2010-11",20,[2821,2822,2823],"Dopamine Activity","Episodic Memory Consolidation","Response Preparation",[2800,2825,2826],"Levodopa\u002Fcarbidopa 125 mg","Domperidon 10 mg",{"intervention":2825,"totalTrials":94,"cells":2828},{"EARLY_PHASE1":2829,"PHASE1":2831,"PHASE2":2833,"PHASE3":2835,"PHASE4":2837,"NA":2839},{"trials":2830,"activeCount":98},[],{"trials":2832,"activeCount":98},[],{"trials":2834,"activeCount":98},[],{"trials":2836,"activeCount":98},[],{"trials":2838,"activeCount":98},[],{"trials":2840,"activeCount":98},[2841],{"nctId":2815,"briefTitle":2816,"status":544,"phases":2842,"primaryCompletion":2211,"completion":2211,"start":2818,"enrollment":2819,"conditions":2843,"interventions":2844},[91],[2821,2822,2823],[2800,2825,2826],{"intervention":2826,"totalTrials":94,"cells":2846},{"EARLY_PHASE1":2847,"PHASE1":2849,"PHASE2":2851,"PHASE3":2853,"PHASE4":2855,"NA":2857},{"trials":2848,"activeCount":98},[],{"trials":2850,"activeCount":98},[],{"trials":2852,"activeCount":98},[],{"trials":2854,"activeCount":98},[],{"trials":2856,"activeCount":98},[],{"trials":2858,"activeCount":98},[2859],{"nctId":2815,"briefTitle":2816,"status":544,"phases":2860,"primaryCompletion":2211,"completion":2211,"start":2818,"enrollment":2819,"conditions":2861,"interventions":2862},[91],[2821,2822,2823],[2800,2825,2826],{"intervention":2864,"totalTrials":94,"cells":2865},"Gadofosveset enhanced MRL of axillary lymph nodes",{"EARLY_PHASE1":2866,"PHASE1":2868,"PHASE2":2870,"PHASE3":2872,"PHASE4":2874,"NA":2876},{"trials":2867,"activeCount":98},[],{"trials":2869,"activeCount":98},[],{"trials":2871,"activeCount":98},[],{"trials":2873,"activeCount":98},[],{"trials":2875,"activeCount":98},[],{"trials":2877,"activeCount":98},[2878],{"nctId":2879,"briefTitle":2880,"status":676,"phases":2881,"primaryCompletion":2882,"completion":2882,"start":2883,"enrollment":2884,"conditions":2885,"interventions":2886},"NCT01609920","Nodal Staging in Breast Cancer With MRL",[91],"2016-05","2012-05",97,[2190],[2864],{"intervention":2888,"totalTrials":94,"cells":2889},"Standard protein enteral nutrition with enteral tracer",{"EARLY_PHASE1":2890,"PHASE1":2892,"PHASE2":2894,"PHASE3":2896,"PHASE4":2898,"NA":2900},{"trials":2891,"activeCount":98},[],{"trials":2893,"activeCount":98},[],{"trials":2895,"activeCount":98},[],{"trials":2897,"activeCount":98},[],{"trials":2899,"activeCount":98},[],{"trials":2901,"activeCount":98},[2902],{"nctId":2903,"briefTitle":2904,"status":544,"phases":2905,"primaryCompletion":2906,"completion":2906,"start":2907,"enrollment":775,"conditions":2908,"interventions":2911},"NCT06104527","Indicator Amino Acid Oxidation in ICU Patients",[91],"2026-03-23","2023-10-30",[2909,2910],"Critical Illness","Muscle Wasting",[2888,2912],"High protein enteral nutrition with enteral tracer",{"intervention":2912,"totalTrials":94,"cells":2914},{"EARLY_PHASE1":2915,"PHASE1":2917,"PHASE2":2919,"PHASE3":2921,"PHASE4":2923,"NA":2925},{"trials":2916,"activeCount":98},[],{"trials":2918,"activeCount":98},[],{"trials":2920,"activeCount":98},[],{"trials":2922,"activeCount":98},[],{"trials":2924,"activeCount":98},[],{"trials":2926,"activeCount":98},[2927],{"nctId":2903,"briefTitle":2904,"status":544,"phases":2928,"primaryCompletion":2906,"completion":2906,"start":2907,"enrollment":775,"conditions":2929,"interventions":2930},[91],[2909,2910],[2888,2912],{"intervention":2932,"totalTrials":94,"cells":2933},"Angiotensin II",{"EARLY_PHASE1":2934,"PHASE1":2936,"PHASE2":2938,"PHASE3":2940,"PHASE4":2942,"NA":2944},{"trials":2935,"activeCount":98},[],{"trials":2937,"activeCount":98},[],{"trials":2939,"activeCount":98},[],{"trials":2941,"activeCount":98},[],{"trials":2943,"activeCount":98},[],{"trials":2945,"activeCount":98},[2946],{"nctId":2947,"briefTitle":2948,"status":544,"phases":2949,"primaryCompletion":2950,"completion":2950,"start":1610,"enrollment":2379,"conditions":2951,"interventions":2953},"NCT01024543","Role of Angiotensin II in Insulin-induced Microvascular Activity",[91],"2009-11",[2952,2730],"Insulin Sensitivity",[2932,2954],"Phenylephrine",{"intervention":2954,"totalTrials":94,"cells":2956},{"EARLY_PHASE1":2957,"PHASE1":2959,"PHASE2":2961,"PHASE3":2963,"PHASE4":2965,"NA":2967},{"trials":2958,"activeCount":98},[],{"trials":2960,"activeCount":98},[],{"trials":2962,"activeCount":98},[],{"trials":2964,"activeCount":98},[],{"trials":2966,"activeCount":98},[],{"trials":2968,"activeCount":98},[2969],{"nctId":2947,"briefTitle":2948,"status":544,"phases":2970,"primaryCompletion":2950,"completion":2950,"start":1610,"enrollment":2379,"conditions":2971,"interventions":2972},[91],[2952,2730],[2932,2954],{"intervention":2974,"totalTrials":94,"cells":2975},"Imiquimod Topical",{"EARLY_PHASE1":2976,"PHASE1":2978,"PHASE2":2980,"PHASE3":2982,"PHASE4":2984,"NA":2986},{"trials":2977,"activeCount":98},[],{"trials":2979,"activeCount":98},[],{"trials":2981,"activeCount":98},[],{"trials":2983,"activeCount":98},[],{"trials":2985,"activeCount":98},[],{"trials":2987,"activeCount":98},[2988],{"nctId":2989,"briefTitle":2990,"status":272,"phases":2991,"primaryCompletion":341,"completion":341,"start":2992,"enrollment":2993,"conditions":2994,"interventions":2995},"NCT06252857","Real-world Evaluation of Diagnostic and Treatment Strategies in Low-Risk Basal Cell Carcinoma",[],"2024-04-22",142,[501],[2974],{"intervention":2997,"totalTrials":94,"cells":2998},"tailored pharmaceutical treatment",{"EARLY_PHASE1":2999,"PHASE1":3001,"PHASE2":3003,"PHASE3":3005,"PHASE4":3007,"NA":3009},{"trials":3000,"activeCount":98},[],{"trials":3002,"activeCount":98},[],{"trials":3004,"activeCount":98},[],{"trials":3006,"activeCount":98},[],{"trials":3008,"activeCount":98},[],{"trials":3010,"activeCount":98},[3011],{"nctId":3012,"briefTitle":3013,"status":544,"phases":3014,"primaryCompletion":3015,"completion":3016,"start":3017,"enrollment":3018,"conditions":3019,"interventions":3023},"NCT04216706","Early Vascular Adjustments to Prevent Preeclampsia",[],"2020-01-01","2020-03-01","2014-11-01",314,[3020,3021,3022],"Preeclampsia","Small for Gestational Age at Delivery","HELLP Syndrome",[2997],{"intervention":3025,"totalTrials":94,"cells":3026},"Acipimox",{"EARLY_PHASE1":3027,"PHASE1":3029,"PHASE2":3031,"PHASE3":3033,"PHASE4":3035,"NA":3037},{"trials":3028,"activeCount":98},[],{"trials":3030,"activeCount":98},[],{"trials":3032,"activeCount":98},[],{"trials":3034,"activeCount":98},[],{"trials":3036,"activeCount":98},[],{"trials":3038,"activeCount":98},[3039],{"nctId":3040,"briefTitle":3041,"status":544,"phases":3042,"primaryCompletion":748,"completion":748,"start":2656,"enrollment":3043,"conditions":3044,"interventions":3047},"NCT00943059","Cross-over Study on Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial Function",[91],31,[3045,3046],"Diabetes Mellitus, Type 2","Cardiomyopathy, Dilated",[3025,3048],"Cellulosum Mycrocryst",{"intervention":3048,"totalTrials":94,"cells":3050},{"EARLY_PHASE1":3051,"PHASE1":3053,"PHASE2":3055,"PHASE3":3057,"PHASE4":3059,"NA":3061},{"trials":3052,"activeCount":98},[],{"trials":3054,"activeCount":98},[],{"trials":3056,"activeCount":98},[],{"trials":3058,"activeCount":98},[],{"trials":3060,"activeCount":98},[],{"trials":3062,"activeCount":98},[3063],{"nctId":3040,"briefTitle":3041,"status":544,"phases":3064,"primaryCompletion":748,"completion":748,"start":2656,"enrollment":3043,"conditions":3065,"interventions":3066},[91],[3045,3046],[3025,3048],{"intervention":3068,"totalTrials":94,"cells":3069},"GADOFOSVESET TRISODIUM 244 Mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Ablavar]",{"EARLY_PHASE1":3070,"PHASE1":3072,"PHASE2":3074,"PHASE3":3076,"PHASE4":3078,"NA":3080},{"trials":3071,"activeCount":98},[],{"trials":3073,"activeCount":98},[],{"trials":3075,"activeCount":98},[],{"trials":3077,"activeCount":98},[],{"trials":3079,"activeCount":98},[],{"trials":3081,"activeCount":98},[3082],{"nctId":3083,"briefTitle":3084,"status":544,"phases":3085,"primaryCompletion":2024,"completion":2024,"start":965,"enrollment":3086,"conditions":3087,"interventions":3091},"NCT01721785","Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer",[],307,[3088,3089,3090],"Rectal Neoplasms","Magnetic Resonance Imaging","Neoplasms Staging",[3068],{"intervention":3093,"totalTrials":94,"cells":3094},"dexchlorpheniramine, lorazepam",{"EARLY_PHASE1":3095,"PHASE1":3097,"PHASE2":3099,"PHASE3":3101,"PHASE4":3103,"NA":3105},{"trials":3096,"activeCount":98},[],{"trials":3098,"activeCount":98},[],{"trials":3100,"activeCount":98},[],{"trials":3102,"activeCount":98},[],{"trials":3104,"activeCount":98},[],{"trials":3106,"activeCount":98},[3107],{"nctId":3108,"briefTitle":3109,"status":544,"phases":3110,"primaryCompletion":3111,"completion":3111,"start":3112,"enrollment":2379,"conditions":3113,"interventions":3114},"NCT00846950","Effects of H1-Antagonist on Cognition",[91],"2007-05","2006-12",[2589],[3093],{"intervention":3116,"totalTrials":94,"cells":3117},"Carnitene",{"EARLY_PHASE1":3118,"PHASE1":3120,"PHASE2":3122,"PHASE3":3124,"PHASE4":3126,"NA":3128},{"trials":3119,"activeCount":98},[],{"trials":3121,"activeCount":98},[],{"trials":3123,"activeCount":98},[],{"trials":3125,"activeCount":98},[],{"trials":3127,"activeCount":98},[],{"trials":3129,"activeCount":98},[3130],{"nctId":3131,"briefTitle":3132,"status":544,"phases":3133,"primaryCompletion":3134,"completion":3134,"start":3135,"enrollment":867,"conditions":3136,"interventions":3137},"NCT03230812","Carnitine Supplementation in Type 2 Diabetic Patients",[91],"2019-11-11","2018-03-01",[1490],[3116],{"intervention":3139,"totalTrials":94,"cells":3140},"Butyrate",{"EARLY_PHASE1":3141,"PHASE1":3143,"PHASE2":3145,"PHASE3":3147,"PHASE4":3149,"NA":3151},{"trials":3142,"activeCount":98},[],{"trials":3144,"activeCount":98},[],{"trials":3146,"activeCount":98},[],{"trials":3148,"activeCount":98},[],{"trials":3150,"activeCount":98},[],{"trials":3152,"activeCount":98},[3153],{"nctId":3154,"briefTitle":3155,"status":544,"phases":3156,"primaryCompletion":3157,"start":3158,"enrollment":1437,"conditions":3159,"interventions":3161},"NCT00726817","The Effects of Butyrate Enemas on Visceral Perception",[91],"2008-02","2007-12",[3160],"Visceral (Hyper)Sensitivity",[3139],{"intervention":3163,"totalTrials":94,"cells":3164},"Genetic analysis for PCSK9 polymorphisms",{"EARLY_PHASE1":3165,"PHASE1":3167,"PHASE2":3169,"PHASE3":3171,"PHASE4":3173,"NA":3175},{"trials":3166,"activeCount":98},[],{"trials":3168,"activeCount":98},[],{"trials":3170,"activeCount":98},[],{"trials":3172,"activeCount":98},[],{"trials":3174,"activeCount":98},[],{"trials":3176,"activeCount":98},[3177],{"nctId":3178,"briefTitle":3179,"status":272,"phases":3180,"primaryCompletion":3181,"completion":3182,"start":3183,"enrollment":1612,"conditions":3184,"interventions":3187},"NCT05503095","PCSK9 Polymorphism and Risk of Cardiac Rupture",[],"2023-08-31","2024-05-31","2022-01-01",[3185,3186],"Post-Infarction Heart Rupture","Gene Polymorphism",[3163],{"intervention":3189,"totalTrials":94,"cells":3190},"beclomethasondipropionate",{"EARLY_PHASE1":3191,"PHASE1":3193,"PHASE2":3195,"PHASE3":3197,"PHASE4":3199,"NA":3201},{"trials":3192,"activeCount":98},[],{"trials":3194,"activeCount":98},[],{"trials":3196,"activeCount":98},[],{"trials":3198,"activeCount":98},[],{"trials":3200,"activeCount":98},[],{"trials":3202,"activeCount":98},[3203],{"nctId":3204,"briefTitle":3205,"status":544,"phases":3206,"primaryCompletion":653,"completion":1052,"start":3207,"enrollment":3208,"conditions":3209,"interventions":3211},"NCT00422747","Early Diagnosis of Asthma in Young Children",[91],"2007-04",202,[3210],"Asthma",[3189],{"intervention":3213,"totalTrials":94,"cells":3214},"ND",{"EARLY_PHASE1":3215,"PHASE1":3217,"PHASE2":3219,"PHASE3":3221,"PHASE4":3223,"NA":3225},{"trials":3216,"activeCount":98},[],{"trials":3218,"activeCount":98},[],{"trials":3220,"activeCount":98},[],{"trials":3222,"activeCount":98},[],{"trials":3224,"activeCount":98},[],{"trials":3226,"activeCount":98},[3227],{"nctId":3228,"briefTitle":3229,"status":544,"phases":3230,"primaryCompletion":3231,"completion":3232,"start":588,"enrollment":1878,"conditions":3233,"interventions":3235},"NCT02376309","The Effect of Nandrolone Decanoate and Leucine on Muscle Loss",[91],"2016-08","2017-08",[3234],"Muscle Atrophy",[3213],{"intervention":3237,"totalTrials":94,"cells":3238},"Acipimox 250 mg Oral",{"EARLY_PHASE1":3239,"PHASE1":3241,"PHASE2":3243,"PHASE3":3245,"PHASE4":3247,"NA":3249},{"trials":3240,"activeCount":98},[],{"trials":3242,"activeCount":98},[],{"trials":3244,"activeCount":98},[],{"trials":3246,"activeCount":98},[],{"trials":3248,"activeCount":98},[],{"trials":3250,"activeCount":98},[3251],{"nctId":3252,"briefTitle":3253,"status":272,"phases":3254,"primaryCompletion":3255,"completion":3255,"start":3256,"enrollment":3257,"conditions":3258,"interventions":3260},"NCT06317142","Glucose and Glycogen Dynamics in Prediabetes",[],"2025-07","2024-02-20",45,[3259],"Pre Diabetes",[3237],{"intervention":3262,"totalTrials":94,"cells":3263},"COVID-19 vaccine",{"EARLY_PHASE1":3264,"PHASE1":3266,"PHASE2":3268,"PHASE3":3270,"PHASE4":3272,"NA":3274},{"trials":3265,"activeCount":98},[],{"trials":3267,"activeCount":98},[],{"trials":3269,"activeCount":98},[],{"trials":3271,"activeCount":98},[],{"trials":3273,"activeCount":98},[],{"trials":3275,"activeCount":98},[3276],{"nctId":3277,"briefTitle":3278,"status":676,"phases":3279,"primaryCompletion":3280,"completion":3280,"start":3281,"enrollment":894,"conditions":3282,"interventions":3283},"NCT04844346","Plant Stanol Esters and COVID-19 Vaccination Response",[91],"2022-01-11","2021-04-22",[28],[3262],{"intervention":3285,"totalTrials":94,"cells":3286},"Carnitor",{"EARLY_PHASE1":3287,"PHASE1":3289,"PHASE2":3291,"PHASE3":3293,"PHASE4":3295,"NA":3297},{"trials":3288,"activeCount":98},[],{"trials":3290,"activeCount":98},[],{"trials":3292,"activeCount":98},[],{"trials":3294,"activeCount":98},[],{"trials":3296,"activeCount":98},[],{"trials":3298,"activeCount":98},[3299],{"nctId":3300,"briefTitle":3301,"status":676,"phases":3302,"primaryCompletion":3303,"completion":3303,"start":2882,"enrollment":21,"conditions":3304,"interventions":3305},"NCT02722902","Carnitine Infusion and Insulin Resistance",[91],"2017-06",[1490],[3285],{"intervention":3307,"totalTrials":94,"cells":3308},"Hold",{"EARLY_PHASE1":3309,"PHASE1":3311,"PHASE2":3313,"PHASE3":3315,"PHASE4":3317,"NA":3319},{"trials":3310,"activeCount":98},[],{"trials":3312,"activeCount":98},[],{"trials":3314,"activeCount":98},[],{"trials":3316,"activeCount":98},[],{"trials":3318,"activeCount":98},[],{"trials":3320,"activeCount":98},[3321],{"nctId":3322,"briefTitle":3323,"status":272,"phases":3324,"primaryCompletion":3325,"completion":3326,"start":3327,"enrollment":3328,"conditions":3329,"interventions":3334},"NCT03288441","Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia",[],"2020-12-31","2021-12-31","2018-03-20",300,[3330,3331,3332,3333],"Hematologic Neoplasms","Thrombocytopenia","Anticoagulants","Platelet Aggregation Inhibitors",[3307,3335,3336,3337,3338,3339],"Prophylactic dose antithrombotic","Change antithrombotic Drug","Change platelet transfusion threshold","Full dose antithrombotics","Intermediate dose antithrombotic",{"intervention":3335,"totalTrials":94,"cells":3341},{"EARLY_PHASE1":3342,"PHASE1":3344,"PHASE2":3346,"PHASE3":3348,"PHASE4":3350,"NA":3352},{"trials":3343,"activeCount":98},[],{"trials":3345,"activeCount":98},[],{"trials":3347,"activeCount":98},[],{"trials":3349,"activeCount":98},[],{"trials":3351,"activeCount":98},[],{"trials":3353,"activeCount":98},[3354],{"nctId":3322,"briefTitle":3323,"status":272,"phases":3355,"primaryCompletion":3325,"completion":3326,"start":3327,"enrollment":3328,"conditions":3356,"interventions":3357},[],[3330,3331,3332,3333],[3307,3335,3336,3337,3338,3339],{"intervention":3336,"totalTrials":94,"cells":3359},{"EARLY_PHASE1":3360,"PHASE1":3362,"PHASE2":3364,"PHASE3":3366,"PHASE4":3368,"NA":3370},{"trials":3361,"activeCount":98},[],{"trials":3363,"activeCount":98},[],{"trials":3365,"activeCount":98},[],{"trials":3367,"activeCount":98},[],{"trials":3369,"activeCount":98},[],{"trials":3371,"activeCount":98},[3372],{"nctId":3322,"briefTitle":3323,"status":272,"phases":3373,"primaryCompletion":3325,"completion":3326,"start":3327,"enrollment":3328,"conditions":3374,"interventions":3375},[],[3330,3331,3332,3333],[3307,3335,3336,3337,3338,3339],{"intervention":3337,"totalTrials":94,"cells":3377},{"EARLY_PHASE1":3378,"PHASE1":3380,"PHASE2":3382,"PHASE3":3384,"PHASE4":3386,"NA":3388},{"trials":3379,"activeCount":98},[],{"trials":3381,"activeCount":98},[],{"trials":3383,"activeCount":98},[],{"trials":3385,"activeCount":98},[],{"trials":3387,"activeCount":98},[],{"trials":3389,"activeCount":98},[3390],{"nctId":3322,"briefTitle":3323,"status":272,"phases":3391,"primaryCompletion":3325,"completion":3326,"start":3327,"enrollment":3328,"conditions":3392,"interventions":3393},[],[3330,3331,3332,3333],[3307,3335,3336,3337,3338,3339],{"intervention":3338,"totalTrials":94,"cells":3395},{"EARLY_PHASE1":3396,"PHASE1":3398,"PHASE2":3400,"PHASE3":3402,"PHASE4":3404,"NA":3406},{"trials":3397,"activeCount":98},[],{"trials":3399,"activeCount":98},[],{"trials":3401,"activeCount":98},[],{"trials":3403,"activeCount":98},[],{"trials":3405,"activeCount":98},[],{"trials":3407,"activeCount":98},[3408],{"nctId":3322,"briefTitle":3323,"status":272,"phases":3409,"primaryCompletion":3325,"completion":3326,"start":3327,"enrollment":3328,"conditions":3410,"interventions":3411},[],[3330,3331,3332,3333],[3307,3335,3336,3337,3338,3339],{"intervention":3339,"totalTrials":94,"cells":3413},{"EARLY_PHASE1":3414,"PHASE1":3416,"PHASE2":3418,"PHASE3":3420,"PHASE4":3422,"NA":3424},{"trials":3415,"activeCount":98},[],{"trials":3417,"activeCount":98},[],{"trials":3419,"activeCount":98},[],{"trials":3421,"activeCount":98},[],{"trials":3423,"activeCount":98},[],{"trials":3425,"activeCount":98},[3426],{"nctId":3322,"briefTitle":3323,"status":272,"phases":3427,"primaryCompletion":3325,"completion":3326,"start":3327,"enrollment":3328,"conditions":3428,"interventions":3429},[],[3330,3331,3332,3333],[3307,3335,3336,3337,3338,3339],{"intervention":3431,"totalTrials":94,"cells":3432},"extrafine HFA-beclomethasone",{"EARLY_PHASE1":3433,"PHASE1":3435,"PHASE2":3437,"PHASE3":3439,"PHASE4":3441,"NA":3443},{"trials":3434,"activeCount":98},[],{"trials":3436,"activeCount":98},[],{"trials":3438,"activeCount":98},[],{"trials":3440,"activeCount":98},[],{"trials":3442,"activeCount":98},[],{"trials":3444,"activeCount":98},[3445],{"nctId":3446,"briefTitle":3447,"status":544,"phases":3448,"completion":1610,"start":3449,"enrollment":3450,"conditions":3451,"interventions":3452},"NCT00402207","The Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Inflammometry",[91],"2005-08",33,[3210],[3431,3453],"HFA-fluticasone",{"intervention":3453,"totalTrials":94,"cells":3455},{"EARLY_PHASE1":3456,"PHASE1":3458,"PHASE2":3460,"PHASE3":3462,"PHASE4":3464,"NA":3466},{"trials":3457,"activeCount":98},[],{"trials":3459,"activeCount":98},[],{"trials":3461,"activeCount":98},[],{"trials":3463,"activeCount":98},[],{"trials":3465,"activeCount":98},[],{"trials":3467,"activeCount":98},[3468],{"nctId":3446,"briefTitle":3447,"status":544,"phases":3469,"completion":1610,"start":3449,"enrollment":3450,"conditions":3470,"interventions":3471},[91],[3210],[3431,3453],{"intervention":3473,"totalTrials":94,"cells":3474},"Pharmacological cardioversion - Flecainide",{"EARLY_PHASE1":3475,"PHASE1":3477,"PHASE2":3479,"PHASE3":3481,"PHASE4":3483,"NA":3485},{"trials":3476,"activeCount":98},[],{"trials":3478,"activeCount":98},[],{"trials":3480,"activeCount":98},[],{"trials":3482,"activeCount":98},[],{"trials":3484,"activeCount":98},[],{"trials":3486,"activeCount":98},[3487],{"nctId":3488,"briefTitle":3489,"status":544,"phases":3490,"primaryCompletion":678,"completion":3491,"start":1165,"enrollment":3492,"conditions":3493,"interventions":3494},"NCT02248753","Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency Department",[91],"2019-12",437,[30],[3473,3495,3496,3497,3498],"Metoprolol","Verapamil","Digoxin","Pharmacological cardioversion - Amiodarone",{"intervention":3495,"totalTrials":94,"cells":3500},{"EARLY_PHASE1":3501,"PHASE1":3503,"PHASE2":3505,"PHASE3":3507,"PHASE4":3509,"NA":3511},{"trials":3502,"activeCount":98},[],{"trials":3504,"activeCount":98},[],{"trials":3506,"activeCount":98},[],{"trials":3508,"activeCount":98},[],{"trials":3510,"activeCount":98},[],{"trials":3512,"activeCount":98},[3513],{"nctId":3488,"briefTitle":3489,"status":544,"phases":3514,"primaryCompletion":678,"completion":3491,"start":1165,"enrollment":3492,"conditions":3515,"interventions":3516},[91],[30],[3473,3495,3496,3497,3498],{"intervention":3496,"totalTrials":94,"cells":3518},{"EARLY_PHASE1":3519,"PHASE1":3521,"PHASE2":3523,"PHASE3":3525,"PHASE4":3527,"NA":3529},{"trials":3520,"activeCount":98},[],{"trials":3522,"activeCount":98},[],{"trials":3524,"activeCount":98},[],{"trials":3526,"activeCount":98},[],{"trials":3528,"activeCount":98},[],{"trials":3530,"activeCount":98},[3531],{"nctId":3488,"briefTitle":3489,"status":544,"phases":3532,"primaryCompletion":678,"completion":3491,"start":1165,"enrollment":3492,"conditions":3533,"interventions":3534},[91],[30],[3473,3495,3496,3497,3498],{"intervention":3497,"totalTrials":94,"cells":3536},{"EARLY_PHASE1":3537,"PHASE1":3539,"PHASE2":3541,"PHASE3":3543,"PHASE4":3545,"NA":3547},{"trials":3538,"activeCount":98},[],{"trials":3540,"activeCount":98},[],{"trials":3542,"activeCount":98},[],{"trials":3544,"activeCount":98},[],{"trials":3546,"activeCount":98},[],{"trials":3548,"activeCount":98},[3549],{"nctId":3488,"briefTitle":3489,"status":544,"phases":3550,"primaryCompletion":678,"completion":3491,"start":1165,"enrollment":3492,"conditions":3551,"interventions":3552},[91],[30],[3473,3495,3496,3497,3498],{"intervention":3498,"totalTrials":94,"cells":3554},{"EARLY_PHASE1":3555,"PHASE1":3557,"PHASE2":3559,"PHASE3":3561,"PHASE4":3563,"NA":3565},{"trials":3556,"activeCount":98},[],{"trials":3558,"activeCount":98},[],{"trials":3560,"activeCount":98},[],{"trials":3562,"activeCount":98},[],{"trials":3564,"activeCount":98},[],{"trials":3566,"activeCount":98},[3567],{"nctId":3488,"briefTitle":3489,"status":544,"phases":3568,"primaryCompletion":678,"completion":3491,"start":1165,"enrollment":3492,"conditions":3569,"interventions":3570},[91],[30],[3473,3495,3496,3497,3498],{"intervention":3572,"totalTrials":94,"cells":3573},"Whole-exome sequencing",{"EARLY_PHASE1":3574,"PHASE1":3576,"PHASE2":3578,"PHASE3":3580,"PHASE4":3582,"NA":3584},{"trials":3575,"activeCount":98},[],{"trials":3577,"activeCount":98},[],{"trials":3579,"activeCount":98},[],{"trials":3581,"activeCount":98},[],{"trials":3583,"activeCount":98},[],{"trials":3585,"activeCount":98},[3586],{"nctId":3587,"briefTitle":3588,"status":272,"phases":3589,"primaryCompletion":3590,"completion":3590,"start":1278,"enrollment":3591,"conditions":3592,"interventions":3595},"NCT02014961","Worm Study: Modifier Genes in Sudden Cardiac Death",[91],"2025-04",223,[3593,3594],"Brugada Syndrome","Long QT Syndrome 3",[3572],{"intervention":2565,"totalTrials":94,"cells":3597},{"EARLY_PHASE1":3598,"PHASE1":3600,"PHASE2":3602,"PHASE3":3604,"PHASE4":3606,"NA":3608},{"trials":3599,"activeCount":98},[],{"trials":3601,"activeCount":98},[],{"trials":3603,"activeCount":98},[],{"trials":3605,"activeCount":98},[],{"trials":3607,"activeCount":98},[],{"trials":3609,"activeCount":98},[3610],{"nctId":2558,"briefTitle":2559,"status":544,"phases":3611,"primaryCompletion":1165,"completion":821,"start":2561,"enrollment":2562,"conditions":3612,"interventions":3613},[91],[15,23],[2533,2565],{"intervention":3615,"totalTrials":94,"cells":3616},"Oxitriptan",{"EARLY_PHASE1":3617,"PHASE1":3619,"PHASE2":3621,"PHASE3":3623,"PHASE4":3625,"NA":3627},{"trials":3618,"activeCount":98},[],{"trials":3620,"activeCount":98},[],{"trials":3622,"activeCount":98},[],{"trials":3624,"activeCount":98},[],{"trials":3626,"activeCount":98},[],{"trials":3628,"activeCount":98},[3629],{"nctId":3630,"briefTitle":3631,"status":544,"phases":3632,"primaryCompletion":1008,"completion":1008,"start":3633,"enrollment":155,"conditions":3634,"interventions":3635},"NCT00731003","The Effect of Serotonergic Modulation on Intestinal Permeability and Visceral Hypersensitivity in Healthy Individuals and Irritable Bowel Syndrome (IBS) Patients",[91],"2009-04",[869],[3615],{"intervention":3637,"totalTrials":94,"cells":3638},"Three different mixture of acetate, butyrate and propionate and palcebo",{"EARLY_PHASE1":3639,"PHASE1":3641,"PHASE2":3643,"PHASE3":3645,"PHASE4":3647,"NA":3649},{"trials":3640,"activeCount":98},[],{"trials":3642,"activeCount":98},[],{"trials":3644,"activeCount":98},[],{"trials":3646,"activeCount":98},[],{"trials":3648,"activeCount":98},[],{"trials":3650,"activeCount":98},[3651],{"nctId":3652,"briefTitle":3653,"status":544,"phases":3654,"primaryCompletion":3655,"completion":3655,"start":2002,"enrollment":1970,"conditions":3656,"interventions":3658},"NCT01983046","Rectal Short Chain Fatty Acids Combinations and Substrate and Energy Metabolism",[91],"2014-02",[15,3657],"Type 2 Diabetes",[3637],{"intervention":3660,"totalTrials":94,"cells":3661},"Pantoprazole",{"EARLY_PHASE1":3662,"PHASE1":3664,"PHASE2":3666,"PHASE3":3668,"PHASE4":3670,"NA":3672},{"trials":3663,"activeCount":98},[],{"trials":3665,"activeCount":98},[],{"trials":3667,"activeCount":98},[],{"trials":3669,"activeCount":98},[],{"trials":3671,"activeCount":98},[],{"trials":3673,"activeCount":98},[3674],{"nctId":3675,"briefTitle":3676,"status":272,"phases":3677,"primaryCompletion":1051,"completion":1051,"start":2552,"enrollment":894,"conditions":3678,"interventions":3680},"NCT01524757","Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis",[91],[3679],"Hemochromatosis",[3660]]